



UNIVERSITY  
OF WOLLONGONG  
AUSTRALIA

University of Wollongong  
Research Online

---

Faculty of Social Sciences - Papers

Faculty of Social Sciences

---

2011

# Dairy constituents and neurocognitive health in ageing

David A. Camfield

*Swinburne University of Technology*, [dcamfield@swin.edu.au](mailto:dcamfield@swin.edu.au)

Lauren Owen

*Swinburne University of Technology*

Andrew Scholey

*Swinburne University of Technology*, [andrew@scholeylab.com](mailto:andrew@scholeylab.com)

Andrew Pipingas

*Swinburne University of Technology*, [apipingas@swin.edu.au](mailto:apipingas@swin.edu.au)

Con Stough

*Swinburne University of Technology*, [cstough@swin.edu.au](mailto:cstough@swin.edu.au)

---

## Publication Details

Camfield, D. A., Owen, L., Scholey, A., Pipingas, A. & Stough, C. (2011). Dairy constituents and neurocognitive health in ageing. *The British Journal of Nutrition: an international journal of nutritional science*, 106 (2), 159-174.

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:  
[research-pubs@uow.edu.au](mailto:research-pubs@uow.edu.au)

---

# Dairy constituents and neurocognitive health in ageing

## **Abstract**

Age-related cognitive decline (ARCD) and dementia are of increasing concern to an ageing population. In recent years, there has been considerable research focused on effective dietary interventions that may prevent or ameliorate ARCD and dementia. While a number of studies have considered the impact that dairy products may have on physiological health, particularly with regard to the metabolic syndrome and cardiovascular health, further research is currently needed in order to establish the impact that dairy products have in the promotion of healthy brain function during ageing. The present review considers the available evidence for the positive effects of dairy products on the metabolic syndrome and glucose regulation, with consideration of the implications for neurocognitive health. A literature search of current (September 2010) meta-analyses/ reviews and original research regarding dairy products and cognition was conducted through SCOPUS using the following search terms for dairy constituents: dairy, milk, cheese, yoghurt, probiotics, whey protein, alpha lactalbumin, calcium, B-12, bioactive peptides and colostrinin (CLN). These search terms for dairy products were combined with the following search terms related to cognition and health: cognition, cognitive decline, dementia, Alzheimer's disease, metabolic syndrome, diabetes, insulin resistance and glucose regulation. Concerns regarding SFA and other fatty acids found in dairy products are also reviewed in relation to different forms of dairy products. The review also considers recent evidence for positive neurocognitive effects associated with bioactive peptides, CLN and proline-rich polypeptides,  $\alpha$ -lactalbumin, vitamin B12, calcium and probiotics. Future directions for the extraction and purification of beneficial constituents are also discussed. It is concluded that low-fat dairy products, when consumed regularly as part of a balanced diet, may have a number of beneficial outcomes for neurocognitive health during ageing.

## **Keywords**

constituents, dairy, ageing, health, neurocognitive

## **Disciplines**

Education | Social and Behavioral Sciences

## **Publication Details**

Camfield, D. A., Owen, L., Scholey, A., Pipingas, A. & Stough, C. (2011). Dairy constituents and neurocognitive health in ageing. *The British Journal of Nutrition: an international journal of nutritional science*, 106 (2), 159-174.

## Review Article

# Dairy constituents and neurocognitive health in ageing

David A. Camfield\*, Lauren Owen, Andrew B. Scholey, Andrew Pipingas and Con Stough

*National Institute of Complementary Medicine – Collaborative Research Centre in Neurocognition, Brain Sciences Institute, Swinburne University of Technology, PO Box 218, Hawthorn, VIC 3122, Australia*

(Received 17 May 2010 – Revised 5 January 2011 – Accepted 7 January 2011 – First published online 22 February 2011)

### Abstract

Age-related cognitive decline (ARCD) and dementia are of increasing concern to an ageing population. In recent years, there has been considerable research focused on effective dietary interventions that may prevent or ameliorate ARCD and dementia. While a number of studies have considered the impact that dairy products may have on physiological health, particularly with regard to the metabolic syndrome and cardiovascular health, further research is currently needed in order to establish the impact that dairy products have in the promotion of healthy brain function during ageing. The present review considers the available evidence for the positive effects of dairy products on the metabolic syndrome and glucose regulation, with consideration of the implications for neurocognitive health. A literature search of current (September 2010) meta-analyses/reviews and original research regarding dairy products and cognition was conducted through SCOPUS using the following search terms for dairy constituents: dairy, milk, cheese, yoghurt, probiotics, whey protein, alpha lactalbumin, calcium, B-12, bioactive peptides and colostrinin (CLN). These search terms for dairy products were combined with the following search terms related to cognition and health: cognition, cognitive decline, dementia, Alzheimer's disease, metabolic syndrome, diabetes, insulin resistance and glucose regulation. Concerns regarding SFA and other fatty acids found in dairy products are also reviewed in relation to different forms of dairy products. The review also considers recent evidence for positive neurocognitive effects associated with bioactive peptides, CLN and proline-rich polypeptides,  $\alpha$ -lactalbumin, vitamin B<sub>12</sub>, calcium and probiotics. Future directions for the extraction and purification of beneficial constituents are also discussed. It is concluded that low-fat dairy products, when consumed regularly as part of a balanced diet, may have a number of beneficial outcomes for neurocognitive health during ageing.

**Key words:** Dairy products: Ageing: Dementia: Cognitive decline: Metabolic syndrome: Bioactive peptides

The world's population is ageing rapidly, with 21% of the population (264 million people) estimated to be 60 years or older in 2009. This estimate is projected to increase to 33% (416 million) by the year 2050<sup>(1)</sup>. The impact of age-related cognitive decline (ARCD) is a major societal health concern, with up to 50% of adults aged 64 years and over reporting difficulties with their memory<sup>(2)</sup>. In addition to normal cognitive decline with ageing, over 20 million people worldwide are also living with dementia, an estimate that is predicted to reach 80 million by the year 2040<sup>(3)</sup>. Alzheimer's disease (AD) is the most common form of dementia, affecting about 10% of the population over the age of 65 years in the USA<sup>(4)</sup>. In response to the reality of an ageing population, there has been increased research focus, in recent years, on the development of effective dietary interventions that may

be preventative against the onset of dementia and help to ameliorate age-related declines in cognitive ability.

Age-related deficits in cognitive abilities have been consistently reported across a range of cognitive domains, including processing speed, attention, episodic memory, spatial ability and executive function<sup>(5–13)</sup>. Longitudinal and cross-sectional brain imaging studies have revealed that ARCD is correlated most strongly with cortical volume decreases in the frontostriatal system<sup>(14–18)</sup>, with decreases in prefrontal cortex volume estimated to occur at a rate of approximately 5%/decade after the age of 20 years<sup>(16,17)</sup>. Age-related reductions in grey matter are due to a number of factors in addition to neuronal loss, including shrinkage of neurons, reduction of synaptic spines and lowered numbers of synapses. In contrast, age-related reductions in white matter may be attributed in

**Abbreviations:** 5-HT, 5-hydroxytryptamine; A $\beta$ ,  $\beta$ -amyloid; AD, Alzheimer's disease; ARCD, age-related cognitive decline; CLN, colostrinin; CNS, central nervous system; Hcy, homocysteine.

\* **Corresponding author:** Dr D. A. Camfield, fax +61 3 9214 5230; email dcamfield@swin.edu.au; david.camfield@gmail.com

part to large reductions in the length of myelinated axons, by as much as 50%<sup>(19)</sup>. Current understanding of ARCD points to multiple aetiological factors in the brain. These include depletion of endogenous antioxidants<sup>(20)</sup>, elevation in NO<sup>(21)</sup> and homocysteine (HCy) levels<sup>(22)</sup>, chronic inflammation<sup>(23)</sup>, glutamatergic excitotoxicity<sup>(24)</sup>, accumulation of redox metals<sup>(25)</sup>, mitochondrial dysregulation<sup>(26)</sup> and Ca dysregulation<sup>(27)</sup>, as well as abnormal insulin levels and/or responsiveness<sup>(28)</sup>.

In the case of AD, additional pathological changes occur in the brain, comprising the formation of extracellular senile plaques from  $\beta$ -amyloid (A $\beta$ ) proteins and intracellular neurofibrillary tangles from  $\tau$  proteins, resulting in widespread damage to neural structures and profound impairment to cognitive abilities<sup>(29–31)</sup>. The current Food and Drug Administration-approved pharmaceutical treatments for dementia are the cholinesterase inhibitors tacrine, donepezil, rivastigmine and galantamine, as well as the *N*-methyl-D-aspartate receptor antagonist memantine<sup>(32,33)</sup>. Despite the recent UK National Institute for Clinical Excellence recommendation to reverse its previous decision and allow these drugs for mild as well as moderate AD, the cholinesterase inhibitors are not always well tolerated, with all four having adverse effects related to cholinergic hyperactivity including nausea, vomiting, diarrhoea, fatigue, muscle cramps and dizziness. There are also few data to support the notion of cholinesterase inhibitors providing any more than symptomatic relief by increasing dwindling levels of acetylcholine as the disease progresses<sup>(34)</sup>. Furthermore, few studies have been conducted that assess the efficacy of cholinesterase inhibitors for longer than 1 year duration or answer the question as to whether they can significantly delay the progression from mild cognitive impairment to AD<sup>(35)</sup>.

In consideration of the diverse aetiology of ARCD and dementia, together with the limitations of current pharmaceutical treatments, attention has turned to consideration of dietary constituents for their potential to simultaneously target multiple mechanisms and play a prophylactic role<sup>(36)</sup>. Epidemiological and prospective cohort studies have identified a number of dietary constituents that are associated with a reduction in ARCD and a lowered risk of dementia. The Mediterranean diet, with a high intake of MUFA from olive oil, high consumption of fish and whole-grain cereals and a moderate intake of red wine, has been found to be protective against ARCD in a number of studies<sup>(37,38)</sup>. Other dietary constituents that have been found to be protective against ARCD are antioxidants, including vitamins E and C, fruit and vegetables and the B vitamins (B<sub>6</sub>, B<sub>12</sub> and folate)<sup>(39)</sup>. Until recently, the efficacy of dairy products in ameliorating ARCD has received comparatively less research focus. However, a growing body of epidemiological research now links dairy consumption to a number of beneficial health outcomes, including lowered risk of the metabolic syndrome, heart disease and stroke<sup>(40)</sup>. In light of the considerable inter-relationship between CVD, the metabolic syndrome and brain function<sup>(41)</sup>, it is timely to assess the impact that dairy constituents have on neurocognitive health. The objective of the present study is to review the evidence linking

different forms of dairy products with amelioration of ARCD, when used regularly as part of the diet over the lifespan. The review also presents current theories regarding likely mechanisms of action by which the main constituents of dairy products may have an impact on neurocognitive health.

## Dairy products and general health

A number of epidemiological studies have provided evidence to suggest that consumption of dairy products, in particular low-fat dairy products, may be associated with a number of beneficial health outcomes. These benefits include a decrease in systolic blood pressure<sup>(42–45)</sup>, a decrease in incidence of type 2 diabetes and insulin resistance<sup>(46–48)</sup>, as well as a decreased risk of stroke and heart disease<sup>(47–49)</sup>. Low-fat dairy product intake has also been found to be associated with decreased levels of inflammatory markers<sup>(50,51)</sup> as well as with a reduced risk of colorectal cancer<sup>(47,52,53)</sup>. In a 65-year follow-up study of the Boyd Orr cohort, a childhood diet that was high in dairy products was not found to be associated with a greater risk of heart disease or stroke, and Ca intake during childhood was found to be inversely associated with stroke mortality<sup>(49)</sup>. A prospective Japanese study has also provided evidence to suggest that milk intake is inversely associated with the risk of developing vascular dementia<sup>(54)</sup>. Conversely, some studies have suggested the possibility of an increased risk of prostate cancer associated with high dairy product consumption, although the evidence is inconsistent<sup>(52,55)</sup>. While much of this evidence has been obtained from epidemiological and prospective cohort studies rather than from randomised controlled clinical trials, it is nonetheless encouraging evidence in support of low-fat dairy products being of positive health benefit.

## Concerns over fatty acid content in dairy products

There is now a general consensus that dietary intake of SFA represents a significant risk factor for CVD, due to elevation of serum LDL-cholesterol<sup>(56)</sup>. Dairy products have been found to be the primary source of dietary SFA<sup>(57)</sup>, with an estimated 40% of all SFA obtained through milk and dairy products in the UK<sup>(58)</sup>; and for this reason, there has been concern that the consumption of dairy products may increase the risk of CVD<sup>(59)</sup>. However, an important distinction needs to be made between milk and other forms of dairy products. The proportion of SFA and other fatty acids in cheese and butter is substantially higher than that found in milk<sup>(60)</sup>. Table 1 lists the fatty acid composition of milk, butter and cheese from a selection of European countries. Here, it can be seen that, while the proportions of fatty acids are roughly equivalent between the three forms of dairy product, the overall total fat content (g/100 g) of butter and cheese is much higher. The epidemiological evidence suggests that it is the ratio of high-fat:low-fat dairy products that is associated with a greater risk of CHD, not dairy consumption *per se*<sup>(61)</sup>. Nevertheless, in consideration of the widespread consumption of bovine milk, investigations have begun into developing

**Table 1.** Fatty acid composition of milk, butter and cheese across European countries\*†

(Mean values and percentages of methyl esters)

Fatty acid class	Milk		Butter		Cheese	
	Mean	%	Mean	%	Mean	%
18:1 <i>t</i>	2.60	0.64	2.91	0.52	2.69	0.57
Total <i>trans</i>	4.26	0.62	4.79	0.75	4.49	0.67
18:0	11.01	0.91	11.07	0.91	11.23	1.22
Total SFA‡	64.74	2.80	63.92	2.07	64.91	2.21
Total <i>cis</i>	26.94	1.97	27.40	1.99	26.64	1.53
Unidentified	3.33	0.74	3.39	0.44	3.22	0.43
Total fat (g/100 g)	3.33	0.78	82.32	3.32	27.27	6.65

\* Countries included are Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Italy, The Netherlands, Norway, Portugal, Spain, Sweden and the UK.

† Adapted from Aro *et al.*<sup>(60)</sup>.

‡ Excluding less than eight-carbon fatty acids.

techniques to reduce the SFA content and increase the *cis*-MUFA content of milk<sup>(62)</sup>.

It is also important to note that certain fatty acids found in milk may not represent as much of a risk factor for CVD as originally thought. There is evidence to suggest that lauric acid (12:0) and myristic acid (14:0) increase the levels of protective HDL-cholesterol, in addition to LDL-cholesterol, thereby helping to reduce the ratio of total cholesterol:HDL-cholesterol<sup>(63,64)</sup>. However, palmitic acid (16:0) has been found to have a less favourable effect on ratios of total cholesterol to HDL-cholesterol<sup>(62)</sup>. In addition to SFA, dairy products also contain a number of other fatty acids. *cis*-MUFA is a fatty acid which has been found to be beneficial in reducing the risk of CVD<sup>(65)</sup>, and dairy products have been found to supply up to 30% of dietary intake of *cis*-MUFA in some European countries<sup>(58)</sup>. *Trans*-fatty acids, which are generally associated with a substantially increased CVD risk<sup>(66)</sup>, are also found in dairy products. It has been estimated that, on average, dairy products contribute 38% of total *trans*-fatty acids across European countries<sup>(58)</sup>. It is worth noting that the isomeric forms of *trans*-fatty acids found in dairy products do not appear to be as detrimental to cardiovascular health as the *trans*-fatty acid isomers that are derived from industrial hydrogenation of vegetable oils<sup>(67)</sup>.

### Dairy and the metabolic syndrome

The cluster of disorders including dyslipidaemia (high fasting TAG levels combined with low HDL-cholesterol levels), hypertension, obesity and glucose intolerance has become grouped together under the umbrella term metabolic syndrome<sup>(68)</sup>. A diet with a low glycaemic index that is high in whole-grain cereal and has a high unsaturated fatty acids:SFA ratio has been found to be associated with a lower prevalence of the metabolic syndrome<sup>(69–71)</sup>. Due to the fatty acid content of milk fat, it was originally suspected that milk consumption would have a negative impact on the metabolic syndrome; however, several studies have subsequently revealed that consumption of milk and other dairy products is inversely correlated with the metabolic syndrome<sup>(69,72,73)</sup>. Various constituents of dairy products that have a beneficial effect

on the metabolic syndrome have been identified; for example, whey protein has been found to be insulinotropic<sup>(74)</sup>, milk peptides and Ca have been found to reduce blood pressure<sup>(75,76)</sup> and milk peptides and Ca may also help reduce plasma cholesterol<sup>(77)</sup>. Ca has been found to have a particularly beneficial effect on serum lipid profiles, with evidence from a number of studies demonstrating that Ca increases HDL-cholesterol while decreasing both total cholesterol and LDL-cholesterol<sup>(73)</sup>. A possible mechanism by which Ca may affect lipoprotein metabolism is through the inhibition of fat absorption in the small intestine<sup>(78)</sup>.

There is increasing evidence of a link between the metabolic syndrome and both cognitive decline and dementia, particularly in individuals with high levels of inflammation<sup>(79,80)</sup>. Epidemiological evidence links many of the components of the metabolic syndrome to increased ARCD and dementia, including hypertension<sup>(81,82)</sup>, diabetes<sup>(83,84)</sup>, dyslipidaemia<sup>(85,86)</sup> and obesity<sup>(87)</sup>. There are a number of mechanisms that may potentially link the metabolic syndrome to cognitive decline. These mechanisms include micro- and macrovascular disease<sup>(88)</sup>, inflammation and atherosclerosis<sup>(89)</sup>, as well as the secretion of inflammatory factors from adipose tissue<sup>(90,91)</sup>. However, perhaps the most important mechanism linking the metabolic syndrome to cognitive decline is that of glucose regulation<sup>(28,92–94)</sup>.

### Glucose regulation and brain function

In healthy, non-diabetic subjects, blood glucose levels peak at approximately 1 h after the start of a meal and then return to baseline levels within 2–3 h<sup>(95,96)</sup>. Within 10 min of food intake, there is a large release of endogenous insulin known as the first-phase insulin response. However, for individuals with increased insulin resistance or type 2 diabetes, the first-phase insulin response is either absent or significantly reduced, resulting in chronically elevated glucose levels throughout the day<sup>(97)</sup>. As a result of prolonged hyperglycaemia, insulin levels also remain high, and with continued elevation of insulin levels, insulin resistance develops<sup>(98)</sup>.

Those with good glucose tolerance, that is those whose blood glucose returns to baseline quickly following a meal, have been shown to demonstrate better memory than those whose blood glucose levels remain elevated for longer periods of time<sup>(99)</sup>. Also in healthy young adults, poor gluco-regulation, and thus a greater increase in blood glucose after a glucose drink, has been associated with poorer performance on tests of memory<sup>(100,101)</sup>, vigilance<sup>(101,102)</sup>, planning<sup>(101)</sup> and dichotic listening<sup>(103)</sup>. Preclinical evidence suggests that feeding young rats with high levels of saturated fats leads to impaired glucose tolerance and reduced insulin sensitivity<sup>(104–106)</sup>, resulting in memory impairment<sup>(107,108)</sup>. One experiment<sup>(109)</sup> examined the impact of gluco-regulation on a variable interval-delayed alternation task, a task that is associated with hippocampal function. Rats fed high-fat diets produced performance deficits, suggesting that impaired glucose regulation moderated hippocampal-dependent memory. However, these deficits were reversed by a 100 mg/kg glucose injection<sup>(109)</sup>. Interestingly, there was no effect of glucose in



animals that received a normal diet, suggesting that glucose was only effective in cases where there was a pre-existing deficit in glucose regulation.

In the elderly, there is a natural decline of gluco-regulation. Messier *et al.*<sup>(110)</sup> compared the cognitive performance of older participants, aged 55–84 years, with better glucose regulation with those with poorer glucose regulation (as measured by the increase in blood glucose from a fasting to peak level following a glucose tolerance test). It was observed that older participants with poorer glucose regulation were impaired in several tests, including verbal memory and arithmetic tasks<sup>(110)</sup>. Some studies have also detected cognitive effects associated with impaired glucose regulation in younger participants, although the impairment is less noticeable in comparison with older participants<sup>(111,112)</sup>. It has been found that those with poorer glucose regulation performed worse on several verbal declarative measures, including immediate and delayed paragraph recall, verbal-free recall and order reconstruction tasks<sup>(111)</sup>. Donohoe & Benton<sup>(113)</sup> performed a glucose tolerance test on undergraduate students and measured blood glucose levels every 30 min following ingestion of a glucose drink. They observed that between 2 and 3 h after the ingestion of 50 g glucose, there was a dip in blood glucose below fasting levels that was followed shortly by a return to fasting levels. They found that the quicker the return to fasting levels, the better the performance on cognitive tests of memory consolidation and retrieval. Other measures of glucose levels did not correlate with memory performance except that faster reaction time was found to be associated with higher baseline blood glucose during the test performance.

A number of other gluco-regulatory indices have been previously evaluated for their relationship with cognitive performance in both younger and older participants. These include fasting blood glucose levels, peak glucose levels, recovery and evoked glucose to baseline levels and incremental area under the curve. Overall evidence suggests that gluco-regulation may exert direct effects on cognitive function so that those with poor gluco-regulation demonstrate mild cognitive deficits in comparison with those with good gluco-regulation<sup>(99,101,111,113–119)</sup>. However, there is evidence to suggest that a long-term deficit in gluco-regulation may also result in chronic cognitive impairments<sup>(120)</sup> and be a contributing factor in the development of ARCD and dementia<sup>(28)</sup>. A number of epidemiological studies have provided evidence to suggest that type 2 diabetes is a significant risk factor for developing dementia<sup>(83,121–123)</sup>.

### Whey protein, obesity and glucose regulation

In bovine milk, whey protein consists of  $\alpha$ -lactalbumin,  $\beta$ -lactoglobulin, IgG, serum albumin, IgA and trace amounts of lactoferrin<sup>(124)</sup>. In terms of protein in the diet, it has been previously observed that free consumption of a high-protein diet increases the rate of fat loss in obese subjects compared with those on low-protein diets<sup>(125)</sup>. It is believed that weight loss by increased density of protein in the diet is due to increased satiety leading to reduced total energy intake

coupled with greater total energy expenditure (due to increased thermogenesis from protein digestion)<sup>(126)</sup>. However, these studies have used mixed protein meals, with more recent research suggesting that the type of protein may be of particular importance for improving body composition. Current evidence suggests that 'complete' proteins that contain all essential amino acids show larger increases in energy expenditure following consumption in comparison with lower-quality proteins<sup>(127)</sup>. Whey protein is not only more complete than other forms of protein such as egg albumin or protein derived from red meat, but also it may offer additional benefits. It is high in branched-chain amino acids, in particular leucine, which means whey is particularly beneficial for preventing muscle-wasting during weight-loss programmes<sup>(128)</sup>. In terms of fat reduction, whey protein concentrate has been shown to reduce body weight in rats<sup>(129,130)</sup>, whereas increased dietary red meat has been demonstrated to increase body weight in rats<sup>(129)</sup>. In a clinical trial with elderly women, a 15 d whey supplement was also found to significantly lower body weight<sup>(131)</sup>.

Obesity has been found to be a significant factor in the development of insulin resistance, due to chronic systemic inflammation in adipose tissue<sup>(132)</sup>. Furthermore, in elderly subjects, there is also a natural decline of gluco-regulation<sup>(110)</sup>. Therefore, any dietary intervention which assists in the maintenance of healthy body weight may also assist in maintaining efficient glucose regulation, which, as mentioned previously, results in better cognitive function both acutely and chronically<sup>(100,101,120)</sup>. In a recent study by Belobrajdic *et al.*<sup>(133)</sup>, insulin-resistant rats fed a high-whey-protein diet for 6 weeks have been found to have significantly reduced energy intake and body fat. In comparison with rats receiving protein in the form of red meat, rats receiving the high-whey-protein diet have also been found to have significantly lower weight gain and significantly increased insulin sensitivity. The authors concluded that the improved insulin sensitivity was due to a reduction of visceral fat.

### Abnormal insulin levels and dementia

Early-stage AD has been found to be associated with high insulin concentrations in response to glucose challenge (hyperinsulinaemia) in combination with reduced insulin-mediated glucose uptake (insulin resistance) in a number of individuals<sup>(134)</sup>. In the central nervous system (CNS), insulin has the effect of promoting the release of intracellular  $A\beta$ <sup>(135)</sup>, with aggregation of  $A\beta$  known to be a central feature of AD pathophysiology<sup>(31)</sup>. In chronic peripheral hyperinsulinaemia, insulin crosses the blood–brain barrier and promotes an increase in the release of  $A\beta$  into extracellular compartments<sup>(28)</sup>. Due to high plasma levels of insulin, there will also be increased concentrations of peripheral  $A\beta$  that will result in obstruction to the clearance of  $A\beta$  from the brain<sup>(28)</sup>. Furthermore, increased levels of insulin in the CNS also inhibit the degradation of  $A\beta$ . This is because insulin-degrading enzyme plays an important role in clearing intracellular  $A\beta$ <sup>(136,137)</sup>, and when there are high levels of insulin in the brain, it must compete with insulin as a target<sup>(28)</sup>.

However, with sustained high levels of insulin in the brain, there is an eventual down-regulation of insulin transport into the brain and inhibition of brain synthesis of insulin<sup>(138,139)</sup>. With a lowered level of insulin in the brain, there is a reduction in the release of A $\beta$  from intracellular compartments as well as a reduction in insulin-degrading enzyme, also bringing about reduced clearance of A $\beta$  from the brain<sup>(28)</sup>. Furthermore, a reduction in ACh and cerebral blood flow has also been found to be associated with low concentrations of insulin in the CNS<sup>(140)</sup>. Thus, both increased and decreased insulin concentrations in the brain contribute to the pathogenesis of AD. In addition to A $\beta$  aggregation, there is also evidence to suggest that low brain concentrations of insulin may lead to an increase in tau hyperphosphorylation<sup>(141)</sup>, while high peripheral insulin levels have been found to exacerbate central inflammation<sup>(142,143)</sup> and oxidative stress<sup>(144)</sup>.

### Influence of whey protein on insulin release

Milk products, in particular the whey fraction, have been found to have an insulinotropic effect both in normal subjects and type 2 diabetics<sup>(74,145,146)</sup>. Whey is a rapidly digested protein, which promotes a higher concentration of amino acids in the plasma following its consumption<sup>(147)</sup>. Amino acids are known to stimulate insulin release in the pancreatic  $\beta$ -cell<sup>(148)</sup>. Nilsson *et al.*<sup>(149)</sup> reported that the branched-chain amino acids leucine, isoleucine and valine, together with lysine and threonine, were the most efficient insulin secretagogues. Table 2 displays the typical amino acids found in whey, together with the quantities (mg/g) from the study by Nilsson *et al.*<sup>(149)</sup>.

The benefit of acute increases in insulin secretion following the consumption of whey protein is that the resultant peak in blood glucose is not as high as it otherwise would be. Frid *et al.*<sup>(146)</sup> reported that the plasma glucose 180 min area under the curve was reduced by 21%, when whey was included in the lunch meal in comparison with a reference meal containing ham. Reducing the postprandial glucose peak has been suggested as a more effective means of treating diabetes than targeting fasting blood glucose levels<sup>(150)</sup>. Epidemiological evidence suggests that, even among overweight individuals, regular dairy product consumption is associated with a significantly lower incidence of the insulin resistance syndrome<sup>(69)</sup>. In light of the evidence suggesting that consumption of dairy products may have a positive effect on glucose regulation<sup>(46)</sup>, it is feasible that there may be acute, as well as chronic, cognitive benefits associated with regular consumption.

### Dairy constituents as direct modulators of cognition

In addition to the cognitive benefits of dairy products associated with improvement to gluco-regulation, there are also a number of components of dairy products that have the potential to influence brain function directly. The composition of milk will be used as an example of the typical components found in dairy products<sup>(151)</sup>: water (85.5–88.7%), milk fat (2.4–5.5%) and solids (non-fat, 7.7–10%). The composition

**Table 2.** Amino acids in whey\*

Amino acid	mg/g
Glu	141.4
Asp	94.1
Leu†	79.8
Lys	76.1
Thr	61.1
Val†	59.3
Ile†	57.3
Pro	46.7
Ala	42.1
Ser	38.8
Cys	22.8
Arg	22.0
Phe	21.3
Tyr	20.8
Met	19.4
His	18.7
Gly	13.8

\* Adapted from Nilsson *et al.*<sup>(149)</sup>.

† Branched-chain amino acids.

of the milk solids may be summarised as follows: lactose 4.6%, protein 3.25% (80% caseins, 20% whey proteins, e.g.  $\alpha$ -lactalbumin and  $\beta$ -lactoglobulin), minerals 0.65% (Ca, P, Mg, K, Na, Zn, Cl, Fe, Cu and sulphate), acids 0.18% (citrate, formate, acetate, lactate and oxalate), enzymes (peroxidase, catalase, phosphatase and lipase) and vitamins (A, B<sub>12</sub>, C, D, thiamin and riboflavin). A growing body of research has now reported positive effects on brain function and cognitive ability that are associated with a number of the components of dairy products.

### Bioactive peptides

Biologically active peptides have been defined as protein fragments that have a positive impact on bodily functions or conditions and may ultimately influence health<sup>(152)</sup>. Milk proteins act as precursors for the formation of bioactive peptides, with the size of the active sequences varying from two to twenty amino acids<sup>(152)</sup>. Casein represents a major proportion (80%) of the protein content in bovine milk, and contains a large quantity of branched-chain amino acids<sup>(153)</sup>. Phosphorylated regions are contained in bovine  $\alpha$ <sub>s1</sub>-casein,  $\alpha$ <sub>s2</sub>-casein and  $\beta$ -casein, regions that may subsequently be released by digestive enzymes<sup>(154)</sup>. The digestive enzymes such as pepsin, trypsin and chymotrypsin have been shown to release a variety of different peptides through hydrolysis of both the casein and whey proteins found in milk. Bioactive peptides are also produced through fermentation of milk with starter cultures, or proteolysis by plant or micro-organism enzymes<sup>(155)</sup>. However, yogurt, cheese and probiotic bacteria have been found to produce different bioactive peptides during milk fermentation<sup>(156)</sup>. Additionally, a great variety of bioactive peptides have also been found to be formed during the cheese-ripening process; e.g. Parmigiano-Reggiano,  $\beta$ -casein *f*(8–16), *f*(58–87),  $\alpha$ <sub>s2</sub>-casein *f*(83–88); Gouda,  $\alpha$ <sub>s1</sub>-casein *f*(1–9),  $\beta$ -casein *f*(60–68); Festivo,  $\alpha$ <sub>s1</sub>-casein *f*(1–9), *f*(1–7), *f*(1–6); Italian varieties of Mozzarella, Crescenza, Italico and Gorgonzola,  $\beta$ -casein *f*(58–72)<sup>(154)</sup>.

A range of different functions have been studied in relation to the biologically active peptides. The most intensively studied function has been that of the blood pressure-reducing (hypotensive) peptides, which inhibit angiotensin-converting enzyme I<sup>(157,158)</sup>. There is evidence to suggest that the angiotensin-converting enzyme I inhibitory potency of cheese increases during the ripening process<sup>(159)</sup>. Casein-derived bioactive peptides with varying angiotensin-converting enzyme I inhibitory potencies have been isolated from a variety of Italian cheeses: Crescenza (37% inhibition), Mozzarella (59% inhibition), Gorgonzola (80% inhibition) and Italo (82% inhibition)<sup>(160)</sup>. In feeding experiments using spontaneously hypertensive rats, reductions in systolic blood pressure have been found to be significant 6 h following ingestion of the cheese varieties Gouda, Blue, Edam and Harvati<sup>(161)</sup>.

A number of bioactive peptides have also been found to be opioid receptor ligands with agonistic or antagonistic activities.  $\beta$ -Casomorphins, which are hydrolysed fragments of  $\beta$ -casein, were the first opioid peptides to be discovered. The adult human intestine has not been found to be permeable to casomorphins, as there has been a failure to detect their presence in the blood plasma following ingestion<sup>(162)</sup>. For this reason, the opioid effects of casomorphins are believed to occur only at a peripheral level, causing a reduction in intestinal transit time and modulating the absorption of amino acids and the transport of electrolytes<sup>(163)</sup>. However, casomorphins have been detected in the plasma of neonates due to their greater intestinal permeability, and, for this reason, it has been suggested that infant formulas may exert a sedative effect on the newborn child<sup>(164)</sup>. Exorphins are another class of milk protein-derived opioids, which include  $\alpha$ -lactorphin peptides corresponding to bovine  $\alpha_{s1}$ -casein *f*(90–96) and bovine  $\alpha$ -lactalbumin *f*(50–53); and  $\beta$ -lactorphin peptides corresponding to bovine  $\beta$ -lactoglobulin *f*(102–105)<sup>(165)</sup>. The exorphins have been shown to exert weak opioid activity in smooth muscles, having a positive effect on the cardiovascular system through vasorelaxation. However, these peptides do not easily cross the blood–brain barrier and have not been found to exert effects in the CNS<sup>(166)</sup>.

Peptides with a range of other functions have also been identified, including Ca-binding phosphopeptides as well as antibacterial and immunomodulatory peptides<sup>(155)</sup>. With particular relevance to nervous system function and the enhancement of cognitive ability, a number of bioactive peptides have also been found to have antioxidative properties. In a review of antioxidative peptides derived from milk, Pihlanto<sup>(167)</sup> identified six peptide fragments derived from casein as well as three peptide fragments derived from  $\beta$ -lactoglobulin, which exerted radical-scavenging abilities and inhibited lipid peroxidation:  $\alpha_{s1}$ -casein *f*(144–149),  $\beta$ -casein *f*(98–105),  $\beta$ -casein *f*(177–183),  $\beta$ -casein *f*(169–176),  $\beta$ -casein *f*(170–176),  $\kappa$ -casein *f*(96–106),  $\beta$ -lactoglobulin *f*(19–29),  $\beta$ -lactoglobulin *f*(145–149),  $\beta$ -lactoglobulin *f*(42–46). It was noted that antioxidative peptides that had been identified so far all contained one or more residues of histidine, proline, tyrosine and tryptophan. Preclinical and clinical studies with fermented milk products have provided preliminary evidence of antioxidant effects associated with these

products. Whey proteins in conjunction with lactic acid bacteria have been shown to have an antiperoxidative action in rats deficient in vitamin E<sup>(168)</sup>. Similarly, in a human clinical intervention study, 21 d supplementation with 150 g/d fermented goats' milk was found to prolong the resistance of the lipoprotein fraction to oxidation, lower the levels of peroxidised lipoproteins, oxidised LDL, 8-isoprostanes and glutathione redox ratio, and enhance total antioxidative activity<sup>(169)</sup>. A recent study by Zemel *et al.*<sup>(170)</sup> has also revealed a significant reduction in both oxidative and inflammatory stress in overweight and obese participants following a 21 d dairy-rich diet.

An important issue to consider is the concentrations of bioactive peptides that are required in order to have a clinically significant effect. The natural concentrations of bioactive proteins found in dairy products are quite low<sup>(124,166)</sup>. Considering that many of the purported physiological effects of bioactive peptides are currently based on *in vitro* research<sup>(166)</sup>, there is a need to conduct clinical trials in humans in order to determine the dose required for clinical effects. A number of techniques are currently under development in order to isolate and enrich the different proteins found in milk. Microbial fermentation using lactic acid bacteria applied to protein-rich raw material is a technique that has the potential to enable large-scale production of bioactive peptides for human consumption<sup>(124)</sup>.

A number of commercially available bioactive peptides have recently become available<sup>(154)</sup>, which may form the basis for future clinical intervention studies in humans. To date, only a handful of clinical studies, largely in relation to antihypertensive bioactive peptides, have been conducted in humans, using milk protein hydrolysates or fermented milk products<sup>(171–175)</sup>. However, a clinical study by Nakamura *et al.*<sup>(153)</sup> has been one of the few studies to examine cognitive effects following intake of a milk casein hydrolysate (0.2 g/kg). The authors reported increased oxyhaemoglobin concentration in the prefrontal cortex and improvements to work efficiency following an acute stressor 60 min after ingestion. These findings corroborated the results of a previous study investigating the effects of a soya protein hydrolysate on brain function<sup>(176)</sup>, although the mechanism of action is unclear. Further clinical trials investigating the efficacy of bioactive peptides in enhancing cognitive function, both acutely and chronically, are currently needed.

### Colostrin and proline-rich polypeptides

Proline is an amino acid that occurs widely in the proteins of both prokaryotic and eukaryotic cells, with a high number of proline residues found in milk caseins<sup>(151)</sup>. Proline has an unusual chemical structure, characterised by a side-chain that is cyclised back on to the backbone amide position. For this reason, proline-rich polypeptides create disturbance in protein structure and are highly bioactive molecules<sup>(177)</sup>. Particularly, high concentrations of proline residues are found in the colostrum, which is the pre-milk fluid produced by the mammary glands of mammals in late pregnancy. The constituents of the colostrum are designed to boost the immunity of the newborn mammal as well as to promote the maturation of the



CNS<sup>(178)</sup>. A comparison of the major milk proteins found in normal milk and the colostrum is displayed in Table 3. Here, it can be seen that there are higher quantities of  $\alpha$ -lactalbumin,  $\beta$ -lactoglobulin and immunoglobulins in the colostrum compared with normal milk. The difference is particularly large for immunoglobulins.

Colostrum-derived proline-rich polypeptides are known as Colostrin™ (CLN), and are obtained from bovine colostrum according to a patented method using alcohol extraction and filtration<sup>(179)</sup>. CLN can be taken in the form of a tablet or capsule and has been characterised as a new cytokine that stimulates a general immune response<sup>(180)</sup>. The yield of proline-rich polypeptides is found to be highest within 6 h of delivery<sup>(181)</sup>. CLN consists of approximately 22% proline, as well as a high proportion of non-polar amino acids, low percentages of glycine, alanine, arginine and histidine and no residues of tryptophan or cysteine<sup>(182)</sup>.

CLN has been found to be effective in reducing oxidative stress, with the research by Zablocka *et al.*<sup>(183)</sup> providing evidence that CLN regulates cytokine secretion and inhibits the production of the superoxide anion and NO *in vivo*. There is also evidence to suggest that CLN has a protective effect against mitochondrial dysfunction and A $\beta$ -induced apoptosis of neurons<sup>(178)</sup>. Furthermore, CLN has been found to improve both spatial learning and incidental memory in rats<sup>(184)</sup>. Some preliminary clinical studies have been conducted to investigate the potential of CLN as a treatment of ARCD and AD.

In a double-blind study of CLN in AD, Leszek *et al.*<sup>(185)</sup> administered CLN, Se or placebo to forty-six AD patients over a 12-month period. A statistically significant improvement in mini-mental state examination score at 12 months was found in those patients receiving CLN who entered the study with mild AD. A trend towards improved outcome was also found for patients receiving CLN who entered the study with moderate or severe AD. CLN was found to be significantly more effective than both placebo and Se in treating AD, with 50% of the CLN-treated patients showing improvement, while only 5% of Se-treated patients showing improvement, and none in the placebo group. In a randomised controlled study by Bilikiewicz & Gaus<sup>(186)</sup>, CLN or placebo was administered to 105 Polish patients with mild-to-moderate AD over a 15-week period. ADAS-cog scores were found to be significantly higher in patients receiving CLN compared with placebo after 15 weeks. The overall benefit analysis revealed that 40% of patients either stabilised or improved on CLN as opposed to only 21% on placebo.

**Table 3.** Concentration of the major proteins of bovine colostrum and milk\*

Protein	Concentration (g/l)	
	Colostrum	Milk
Caseins ( $\alpha_{s1}$ , $\alpha_{s2}$ , $\beta$ and $\kappa$ )	26	28
$\beta$ -Lactoglobulin	8.0	3.3
$\alpha$ -Lactalbumin	3.0	1.2
Immunoglobulins	20–150	0.5–1.0

\* Adapted from Korhonen & Pihlanto<sup>(124)</sup>.

## $\alpha$ -Lactalbumin

$\alpha$ -Lactalbumin comprises approximately 3.4% of the total protein content of bovine milk<sup>(187)</sup> and is the predominant whey protein in human milk, with levels increasing from 21 to 34% between days 1 and 14 of lactation<sup>(188)</sup>. In addition to the bio-active peptides that result from the partly hydrolysed protein, there are also a number of important amino acids that are released from the fully digested protein.  $\alpha$ -Lactalbumin is a particularly good source of the essential amino acids tryptophan and cysteine. Tryptophan is a precursor of serotonin (5-hydroxytryptamine, 5-HT), while cysteine is a precursor of the endogenous antioxidant glutathione<sup>(189)</sup>.  $\alpha$ -Lactalbumin protein contains the highest tryptophan content of all food protein sources (6%)<sup>(190)</sup>. By increasing the blood plasma ratio of tryptophan:other large amino acids, there is greater transport of tryptophan across the blood–brain barrier, which results in enhanced 5-HT synthesis in the brain<sup>(191)</sup>.

Previously, it has been demonstrated that  $\alpha$ -lactalbumin containing 1.3 g tryptophan/100 g causes a 48% increase in plasma tryptophan:large neutral amino acids<sup>(192)</sup>, and more recently, it has been observed that evening consumption of  $\alpha$ -lactalbumin with a tryptophan content of 4.8 g/100 g increased plasma tryptophan by 130%<sup>(193)</sup>. Furthermore, in preclinical research with rodents,  $\alpha$ -lactalbumin has been found to increase brain 5-HT concentrations<sup>(194)</sup>. Raising brain serotonin might have a number of beneficial effects on mood and cognitive function. In terms of stress, raised serotonin might attenuate the effects of reduced neurogenesis that occurs following stress and throughout the ageing process<sup>(195)</sup>. In terms of sleep, serotonin up-regulation may improve sleep deficiencies and abnormalities affecting cognition, which occur in young and elderly individuals due to deficient brain 5-HT activity<sup>(196)</sup>.

Behavioural findings show that serotonin raised by  $\alpha$ -lactalbumin restores sleep in rats that are sleep-deprived through food deprivation<sup>(197)</sup>. In humans, increases in plasma tryptophan availability for uptake into the brain have been shown to enhance sustained alertness early in the morning after an overnight sleep, a finding that has been attributed to improved sleep<sup>(193)</sup>. Furthermore,  $\alpha$ -lactalbumin has been shown to improve mood and information processing, as well as to attenuate stress-induced cortisol responses in stress-vulnerable subjects (with high neuroticism scores) but not in controls (low neuroticism scores)<sup>(198,199)</sup>. Research by Schmitt *et al.*<sup>(200)</sup> in premenstrual women, who typically display serotonergic hypofunction, revealed that acute administration of  $\alpha$ -lactalbumin protein ameliorated memory performance deficits in long-term memory for abstract figures.

Since the serotonin system is important in the regulation of mood as well as cognitive function, the use of  $\alpha$ -lactalbumin to relieve depressive symptoms has also previously been investigated. The current treatments for depression largely work by inhibiting the reuptake of serotonin (preventing breakdown and reabsorption in order to increase circulating serotonin). Selective serotonin re-uptake inhibitors have been found to relieve depressive symptoms in both animal and human models<sup>(201)</sup>. Conversely, depletion of tryptophan

induces depressive symptoms in depression-vulnerable individuals (for a review, see Booij *et al.*<sup>(202)</sup>). In preclinical research with rats,  $\alpha$ -lactalbumin-enriched diets have been found to enhance serotonin release and induce anxiolytic (antipanic or anti-anxiety agent) and rewarding effects<sup>(194)</sup>.

However, in humans, recovered depressive individuals and control subjects who were subjected to a laboratory stressor showed only modest improvements to mood and cortisol response to experimental stress following acute administration of a drink containing 20 g  $\alpha$ -lactalbumin<sup>(203)</sup>. The authors suggested that acute administration of  $\alpha$ -lactalbumin was not sufficient to prevent a stress-induced mood deterioration or cortisol response<sup>(203)</sup> in recovered depressed subjects. In a later study, also examining the effects of  $\alpha$ -lactalbumin in recovered depressed patients, again, significant improvement to mood has been observed. However, both recovered depressive subjects and control subjects demonstrated improved cognitive ability following  $\alpha$ -lactalbumin administration<sup>(204)</sup>. In a recent study by Verschoor *et al.*<sup>(205)</sup>, acute administration of a drink containing 20 g  $\alpha$ -lactalbumin has not been found to significantly affect the mood or appetite following an acute stressor, although a lower liking for sweet foods has been observed in those with high trait anxiety. Taken together, the data suggest that enhancing 5-HT function through dietary tryptophan may be beneficial for improving sleep, mood and cognitive functioning and may particularly benefit vulnerable individuals coping with high levels of stress. However, it is important to note that the clinical studies reviewed have used drinks with the levels of  $\alpha$ -lactalbumin far in excess of that which would be found in normal dairy products. As shown in Table 3, 1.2 g  $\alpha$ -lactalbumin per litre is typically found in normal milk, which is a much smaller quantity in comparison with the 20 g typically used in intervention studies<sup>(203–205)</sup>. Thus, in order to see clinically significant effects on cognition or mood associated with  $\alpha$ -lactalbumin, a drink with fortified levels would need to be taken.

### Vitamin B<sub>12</sub>

Dairy products are a natural dietary source of vitamin B<sub>12</sub>, with one cup of yogurt providing about 25% of the recommended daily intake, and one cup of milk contributing about 10% of the recommended daily intake of B<sub>12</sub><sup>(206)</sup>. Maintaining adequate dietary levels of B<sub>12</sub> is important for healthy brain ageing, with epidemiological research linking vitamin B<sub>12</sub> deficiency to a greater risk of developing AD<sup>(22,207,208)</sup>. A study by Wang *et al.*<sup>(209)</sup> has reported that out of 370 elderly people monitored over a 3-year period, vitamin B<sub>12</sub> as well as folate deficiency was associated with double the risk of developing AD. Research by Nilsson *et al.*<sup>(210)</sup> has reported decreased serum vitamin B<sub>12</sub> levels in 69% of demented and non-demented psychogeriatric patients. In another study, this group reported significant improvement to mini-mental state examination scores in a mild-to-moderate dementia group following 2-month treatment with vitamin B<sub>12</sub> as well as folate<sup>(211)</sup>. Unfortunately, the majority of epidemiological studies do not consider vitamin B<sub>12</sub> in isolation from folate, and for this reason, it is difficult to discern the relative

contribution of each to the risk of developing dementia. However, current theoretical understanding regarding the relationship between B<sub>12</sub> deficiency and accumulation of the amino acid Hcy suggests that it plays an important role in the maintenance of healthy brain function<sup>(212)</sup>.

There is strong evidence to suggest that vitamin B<sub>12</sub> deficiency brings about cognitive decline due to an excess build-up of the amino acid Hcy. Vitamin B<sub>12</sub>, together with folate, is a cofactor for enzymes that recycle Hcy back to methionine, and when they are not present in adequate amounts, the methionine–Hcy cycle is disrupted, which has a significant impact on cognitive function<sup>(212)</sup>. Hcy, an amino acid produced by the metabolism of methionine, has been found to be a biomarker in its own right for elevated risk of developing AD. Hcy is normally metabolised in one of two ways; it is either converted back to methionine by re-methylation or converted to taurine and cysteine through trans-sulfuration. Abnormally high levels of Hcy signal a breakdown in these biochemical processes. If not enough Hcy is converted back to methionine, this has important implications for brain function<sup>(212)</sup>.

The methionine cycle involves the conversion of methionine to *S*-adenosylmethionine, which is the most important methyl donor in the human body required for methylation of a host of substances, including DNA and proteins such as myelin. After donating its methyl group, *S*-adenosylmethionine becomes *S*-adenosylhomocysteine and then Hcy after losing its adenosine. If Hcy is not metabolised properly, there will be insufficient *S*-adenosylmethionine available, and this will result in the inhibition of methylation<sup>(212)</sup>. The gene for the amyloid precursor protein is heavily methylated. Decreased methylation may lead to the promotion of gene mutations involved in the increased expression of amyloid precursor protein and extracellular deposition of the A $\beta$  peptide<sup>(213,214)</sup>. Furthermore, accumulation of Hcy itself, as well as *S*-adenosylhomocysteine, in the body has been found to cause oxidative stress, excitotoxicity in neurons, as well as DNA strand breakage and mitochondrial membrane damage<sup>(215)</sup>. There is also evidence to suggest that excess Hcy makes neurons more sensitive to A $\beta$  toxicity<sup>(216)</sup>.

Total levels of plasma Hcy have been found to increase with age, reaching a plateau at about the age of 60 years<sup>(217)</sup>. In a study of Hcy levels in histologically confirmed AD patients by Clarke *et al.*<sup>(218)</sup>, it has been found that people in the top third of Hcy levels had a 4.5 times greater risk of AD compared with those in the bottom third. The Framingham Study<sup>(217)</sup>, which followed up 1092 people for 8 years, has found high Hcy levels to be associated with double the risk for AD. A more recent 4.5-year longitudinal study by Haan *et al.*<sup>(22)</sup> on 1779 Mexican Americans over the age of 60 years reported 2.39 times the risk of dementia or cognitive impairment associated with high Hcy levels at baseline. High levels of Hcy are concomitantly observed with low levels of the recycling cofactors vitamin B<sub>12</sub> and folate. In a study by Joosten *et al.*<sup>(219)</sup> comparing fifty-two AD patients with forty-nine elderly people living at home and fifty hospitalised non-demented controls, the AD group has been found to have the highest levels of Hcy and the lowest levels of vitamin B<sub>12</sub>. The evidence thus far implicates vitamin

B<sub>12</sub> as an important vitamin for maintaining proper metabolism of Hcy, without which the brain becomes more susceptible to oxidative damage and apoptosis. As an important dietary source of vitamin B<sub>12</sub>, dairy products are likely to play an important role in ensuring adequate Hcy metabolism, particularly during ageing.

## Calcium

It has been estimated that dairy products contribute 70.3% of Ca in the US diet<sup>(220)</sup>. If dairy products are excluded from the diet, then it is difficult to meet the recommended Ca intake<sup>(221)</sup>. There is strong evidence from both epidemiological studies and randomised clinical trials to suggest that higher consumption of dairy products may be associated with lower rates of obesity<sup>(222)</sup>. One mechanism by which dairy products may lead to weight reduction is an increase in satiety due to the consumption of dairy proteins<sup>(223)</sup>. However, perhaps the most significant contribution to weight loss associated with dairy product consumption is due to the impact of Ca on fat excretion. A meta-analysis by Astrup *et al.*<sup>(222)</sup> has revealed that increasing dairy Ca consumption by 1200 mg/d resulted in increased faecal fat excretion by 5.2 g/d. Ca forms insoluble fatty acid soaps and other hydrophobic aggregations of bile acids, P and fatty acids in the small intestine, resulting in a greater excretion of fat<sup>(224,225)</sup>. Serum cholesterol levels have also been found to be lowered following supplementation with calcium phosphate, as a result of increased bile excretion and regeneration of bile acids from endogenous cholesterol<sup>(226)</sup>.

In contrast to the positive effects of Ca on obesity and cholesterol, there have been some concerns regarding high intakes of Ca and increased vascular calcification. A cross-sectional study by Payne *et al.*<sup>(227)</sup> has found evidence to suggest that Ca and vitamin D intake was positively correlated with brain lesion volume in a sample of elderly adults. Similar findings were reported by Bolland *et al.*<sup>(228)</sup> in a Ca supplementation study of bone mineral density in elderly women. Those women randomised to receive Ca supplementation were found to be twice as likely of suffering a myocardial infarction in comparison with the placebo group over a 5-year period. A recent supplementation study by Daly *et al.*<sup>(229)</sup> has also reported that abdominal aortic calcification increased in men receiving Ca and vitamin D<sub>3</sub> fortified milk in comparison with the control group over a 2-year period. Further research is currently needed in order to determine the dose at which vitamin D and/or Ca increases the risk of vascular calcification.

Ca dysregulation has been proposed as an important factor in brain ageing and neurodegeneration<sup>(27,230)</sup> as well as in the metabolic syndrome<sup>(231)</sup>. Larger Ca<sup>2+</sup>-dependent afterhyperpolarisation associated with action potentials has been found in cortical and hippocampal neurons of older compared with younger animals<sup>(232–237)</sup>. Larger Ca<sup>2+</sup> transients during repetitive spike trains<sup>(238,239)</sup>, larger whole-cell Ca<sup>2+</sup> currents<sup>(240)</sup> and excess Ca<sup>2+</sup> influx into neurons via voltage-gated Ca<sup>2+</sup> channels have also been found to be associated with ageing, with many of these changes also found to be

associated with age-related cognitive deficits<sup>(230,241)</sup>. Elevated Ca<sup>2+</sup> release from ryanodine receptors is a contributing factor to cell death<sup>(230)</sup>, with ryanodine receptor expression altered in some AD mutations (e.g. presenilin 1)<sup>(232,242)</sup>. However, it is important to note that there is currently no evidence to suggest that dietary intake of Ca is a causative factor in age-related Ca dysregulation.

## Probiotics

Probiotics are live microbial food supplements that have a beneficial effect on intestinal microbial balance, with the most frequently used bacteria in commercially available fermented milk and yogurts being the *Lactobacillus* and *Bifidobacterium* species<sup>(243)</sup>. The research assessing the effects of probiotics on brain function is in its very early stages. However, research suggests that bacteria in the gastrointestinal tract can communicate with the CNS, and may have immune- and non-immune-related effects beyond the gastrointestinal tract<sup>(243)</sup>. Studies on clinical populations such as the chronic fatigue syndrome and fibromyalgia, where lower levels of bifidobacterium and higher levels of lactic acid bacteria have been reported, have found evidence to suggest that poorer gut health is correlated with more severe neurological and cognitive deficits such as nervousness, memory loss, forgetfulness and confusion<sup>(244)</sup>.

A possible explanation for the link between gut health and cognition is the effect of pro-inflammatory cytokines in the CNS. It has been suggested that the effect of probiotics on systemic inflammatory cytokines and oxidative stress may ultimately lead to an increase in brain-derived neurotrophic factor<sup>(245)</sup>. A preclinical study by Desbonnet *et al.*<sup>(246)</sup> has revealed that 14 d of treatment with the probiotic *Bifidobacterium infantis* resulted in a significant attenuation of pro-inflammatory cytokines, together with a significant increase in the serotonin precursor tryptophan. These findings are indicative of an antidepressant effect, and have led to the recent suggestion that probiotics may be used as an adjunct treatment for major depressive disorder<sup>(245)</sup>.

There have been few studies to directly assess the effects of probiotics on cognition. A study by Benton *et al.*<sup>(247)</sup> has been one of the few chronic intervention studies to directly investigate the effects of probiotics on cognition. However, the effects on cognition were not in the direction that might have been expected. At day 20 of the intervention, individuals in the probiotic group were found to perform significantly worse on a test of semantic memory in comparison with placebo. However, considering the scarcity of other studies to investigate the cognitive effects associated with probiotics, further research is required to corroborate these findings.

## Summary

The use of dairy products in the prevention or amelioration of normal ARCD and dementia is of growing interest. A number of components present in dairy products may have a substantial impact on the physiological factors associated with ageing and dementia. As with other dietary interventions which

influence cognitive function, the impact of dairy products on neurocognition is modulated by individual differences. Some of these may be specific to dairy, such as lactose intolerance<sup>(248)</sup>, although the area is rather under-researched. Dairy consumption, in particular low-fat dairy, has been found to be associated with a lowered incidence of the metabolic syndrome, with positive effects on cognition through improved glucose regulation and weight management associated with whey protein and Ca. In order to reduce the health risks associated with saturated fats, it is recommended that low-fat dairy be consumed as part of the regular diet in preference to high-fat dairy. A number of bioactive peptides originating from dairy products have been found to have a beneficial effect on cardiovascular function, as well as on antioxidant and anti-inflammatory properties. However, the natural concentrations of these peptides are relatively low, and manufacturing techniques are currently needed in order to further isolate and enrich these beneficial peptides. CLN is a form of dairy product that has been found to be effective in reducing oxidative stress and inflammation, and has shown potential in the treatment of patients with mild AD.  $\alpha$ -Lactalbumin from whey protein has been found to be beneficial in increasing the levels of serotonin, with preliminary data suggesting potentially beneficial effects on sleep, mood and cognition, particularly in individuals vulnerable to stress. However, currently, the quantity of  $\alpha$ -lactalbumin found in normal milk is inadequate to achieve clinically significant effects, and for this reason, the quantity must be fortified. Vitamin B<sub>12</sub> has been found to be an important dietary constituent that is required for effective HCy metabolism, with dairy products being a major source of vitamin B<sub>12</sub> in the diet. Dairy products are also a major source of dietary Ca, with Ca consumption associated with lower rates of obesity and lowered serum cholesterol levels. However, there has been some concern that increased Ca intake may be linked to an increase in vascular calcification. Probiotics have also been found to have a positive effect on neurocognitive health by attenuating pro-inflammatory cytokine activity and increasing levels of tryptophan and brain-derived neurotrophic factor. In conclusion, current evidence suggests that the regular consumption of low-fat dairy products as part of a balanced diet may have a number of positive effects on neurocognitive health in ageing.

### Acknowledgements

The present study was supported by Dairy Innovation Australia Limited. There are no conflicts of interest concerning any authors involved with the preparation of the manuscript. D. A. C. conducted the literature review as well as preparation of the final manuscript. L. O. was also involved in conducting the literature review. A. P. contributed information to the manuscript regarding the cognitive effects of ageing. A. B. S. was involved in editing the final manuscript. C. S. was involved in editing the final manuscript.

### References

1. United Nations (2009) World Population Prospects: The 2008 Revision, Highlights, Working Paper. no. ESA/P/
2. Reid LM & MacLulich AMJ (2006) Subjective memory complaints and cognitive impairment in older people. *Dement Geriatr Cogn Disord* **22**, 471–485.
3. Ferri CP, Prince M, Brayne C, *et al.* (2005) Global prevalence of dementia: a Delphi Consensus Study. *Lancet* **366**, 2112–2117.
4. Mishra S & Palanivelu K (2008) The effect of curcumin (turmeric) on Alzheimer's disease: an overview. *Ann Indian Acad Neurol* **11**, 13–19.
5. Zelinski EM & Burnight KP (1997) Sixteen-year longitudinal and time lag changes in memory and cognition in older adults. *Psychol Aging* **12**, 503–513.
6. Schaie KW (1996) *Intellectual Development in Adulthood: The Seattle Longitudinal Study*. New York: Cambridge University Press.
7. Craik FIM (1994) Memory changes in normal aging. *Curr Dir Psychol Sci* **3**, 155–158.
8. Park DC, Lautenschlager G, Smith AD, *et al.* (1996) Mediators of long-term memory performance across the life span. *Psychol Aging* **11**, 621–637.
9. Park DC, Lautenschlager G, Hedden T, *et al.* (2002) Models of visuospatial and verbal memory across the adult life span. *Psychol Aging* **17**, 299–320.
10. Hultsch DF, MacDonald SWS & Dixon RA (2002) Variability in reaction time performance of younger and older adults. *J Gerontol B Psychol Sci Soc Sci* **57**, M228–M235.
11. Salthouse TA (1996) The processing-speed theory of adult age differences in cognition. *Psychol Rev* **103**, 403–428.
12. Rabbitt P & Lowe C (2000) Patterns of cognitive ageing. *Psychol Res* **63**, 308–316.
13. Verhaeghen P & Cerella J (2002) Aging, executive control, and attention: a review of meta-analyses. *Neurosci Biobehav Rev* **26**, 849–857.
14. Bugg JM, Zook NA, DeLosh EL, *et al.* (2006) Age differences in fluid intelligence: contributions of general slowing and frontal decline. *Brain Cogn* **62**, 9–16.
15. Schretlen D, Pearlson GD, Anthony JC, *et al.* (2000) Elucidating the contributions of processing speed, executive ability, and frontal lobe volume to normal age-related differences in fluid intelligence. *J Int Neuropsychol Soc* **6**, 52–61.
16. Hedden T & Gabrieli JDE (2004) Insights into the ageing mind: a view from cognitive neuroscience. *Nat Rev Neurosci* **5**, 87–96.
17. Kramer AF, Fabiani M & Colcombe SJ (2006) Contributions of cognitive neuroscience to the understanding of behaviour and aging. In *Handbook of the Psychology of Aging*, pp. 57–83 [JE Birren and KW Schaie, editors]. Burlington, MA: Elsevier Academic Press.
18. West RL (1996) An application of prefrontal cortex function theory to cognitive aging. *Psychol Bull* **120**, 272–292.
19. Fjell AM & Walhovd KB (2010) Structural brain changes in aging: courses, causes and cognitive consequences. *Rev Neurosci* **21**, 187–221.
20. Gracy RW, Talent JM, Kong Y, *et al.* (1999) Reactive oxygen species: the unavoidable environmental insult? *Mutat Res* **428**, 17–22.
21. Calabrese V, Mancuso C, Calvani M, *et al.* (2007) Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. *Nat Rev Neurosci* **8**, 766–775.
22. Haan MN, Miller JW, Aiello AE, *et al.* (2007) Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. *Am J Clin Nutr* **85**, 511–517.



23. Zipp F & Aktas O (2006) The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. *Trends Neurosci* **29**, 518–527.
24. Hynd MR, Scott HL & Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. *Neurochem Int* **45**, 583–595.
25. Rogers JT & Lahiri DK (2004) Metal and inflammatory targets for Alzheimer's disease. *Curr Drug Targets* **5**, 535–551.
26. Kidd PM (2005) Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. *Altern Med Rev* **10**, 268–293.
27. Thibault O, Porter NM, Chen KC, *et al.* (1998) Calcium dysregulation in neuronal aging and Alzheimer's disease: history and new directions. *Cell Calcium* **24**, 417–433.
28. Craft S & Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. *Lancet Neurol* **3**, 169–178.
29. Kidd PM (2008) Alzheimer's disease, amnesic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. *Altern Med Rev* **13**, 85–115.
30. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev* **81**, 741–766.
31. Hardy J & Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* **297**, 353–356.
32. Wang BS, Wang H, Wei ZH, *et al.* (2009) Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. *J Neural Transm* **116**, 457–465.
33. May BH, Lit M, Xue CC, *et al.* (2009) Herbal medicine for dementia: a systematic review. *Phytother Res* **23**, 447–459.
34. Jones RW (2003) Have cholinergic therapies reached their clinical boundary in Alzheimer's disease? *Int J Geriatr Psychiatry* **18**, Suppl. 1, S7–S13.
35. Raina P, Santaguida P, Ismaila A, *et al.* (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. *Ann Intern Med* **148**, 379–397.
36. Van der Schyf CJ, Gal S, Geldenhuys WJ, *et al.* (2006) Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. *Expert Opin Investig Drugs* **15**, 873–886.
37. Panza F, Solfrizzi V, Colacicco AM, *et al.* (2004) Mediterranean diet and cognitive decline. *Health Nutr* **7**, 959–963.
38. Solfrizzi V, Panza F & Capurso A (2003) The role of diet in cognitive decline. *J Neural Transm* **110**, 95–110.
39. Smith PJ & Blumenthal JA (2010) Diet and neurocognition: review of evidence and methodological considerations. *Curr Aging Sci* **3**, 57–66.
40. Weaver CM (2010) Role of dairy beverages in the diet. *Physiol Behav* **100**, 63–66.
41. Keller JN (2009) Special issue: reciprocal interactions between diet, metabolism, and the nervous system. *Biochim Biophys Acta* **1792**, 393–394.
42. van Meijl LEC & Mensink RP (2010) Low-fat dairy consumption reduces systolic blood pressure, but does not improve other metabolic risk parameters in overweight and obese subjects. *Nutr Metab Cardiovasc Dis* (Epublication ahead of print version 11 February 2010).
43. Engberink MF, Hendriksen MAH, Schouten EG, *et al.* (1883) Inverse association between dairy intake and hypertension: The Rotterdam Study. *Am J Clin Nutr* **89**, 1877–1883.
44. Toledo E, Delgado-Rodríguez M, Estruch R, *et al.* (2009) Low-fat dairy products and blood pressure: follow-up of 2290 older persons at high cardiovascular risk participating in the PREDIMED study. *Br J Nutr* **101**, 59–67.
45. Engberink MF, Geleijnse JM, De Jong N, *et al.* (2009) Dairy intake, blood pressure, and incident hypertension in a general Dutch population. *J Nutr* **139**, 582–587.
46. Ūnal G, Akalin AS & Akbulut N (2008) Importance of dairy products in metabolic syndrome – cardiovascular disease, insulin resistance and diabetes, and hypertension (Part 2). *Agro Food Ind HiTech* **19**, 32–34.
47. Elwood PC, Givens DI, Beswick AD, *et al.* (2008) The survival advantage of milk and dairy consumption: an overview of evidence from cohort studies of vascular diseases, diabetes and cancer. *J Am Coll Nutr* **27**, 723S–734S.
48. Elwood PC, Pickering JE, Givens DI, *et al.* (2010) The consumption of milk and dairy foods and the incidence of vascular disease and diabetes: an overview of the evidence. *Lipids* **45**, 925–939.
49. Van Der Pols JC, Gunnell D, Williams GM, *et al.* (2009) Childhood dairy and calcium intake and cardiovascular mortality in adulthood: 65-year follow-up of the Boyd Orr cohort. *Heart* **95**, 1600–1606.
50. Esmailzadeh A & Azadbakht L (2010) Dairy consumption and circulating levels of inflammatory markers among Iranian women. *Public Health Nutr* **13**, 1395–1402.
51. van Meijl LEC & Mensink RP (2010) Effects of low-fat dairy consumption on markers of low-grade systemic inflammation and endothelial function in overweight and obese subjects: an intervention study. *Br J Nutr* **104**, 1523–1527.
52. Huncharek M, Muscat J & Kupelnick B (2009) Colorectal cancer risk and dietary intake of calcium, vitamin D, and dairy products: a meta-analysis of 26 335 cases from 60 observational studies. *Nutr Cancer* **61**, 47–69.
53. Pufulete M (2008) Intake of dairy products and risk of colorectal neoplasia. *Nutr Res Rev* **21**, 56–67.
54. Yamada M, Kasagi F, Sasaki H, *et al.* (2003) Association between dementia and midlife risk factors: the radiation effects research foundation Adult Health Study. *J Am Geriatr Soc* **51**, 410–414.
55. Huncharek M, Muscat J & Kupelnick B (2008) Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26 769 cases from 45 observational studies. *Nutr Cancer* **60**, 421–441.
56. Zock PL (2006) Health problems associated with saturated and trans fatty acids intake. In *Improving the Fat Content of Foods*, pp. 3–24 [C Williams and J Buttriss, editors]. Boca Raton, FL: CRC Press.
57. Henderson L, Gregory J, Irving K, *et al.* (2003) *National diet and nutrition survey: adults aged 19 to 64 years. vol 2: Energy, Protein, Carbohydrate, Fat and Alcohol Intake*. London: The Stationery Office.
58. Hulshof KFAM, Van Erp-Baart MA, Anttolainen M, *et al.* (1999) Intake of fatty acids in Western Europe with emphasis on trans fatty acids: The TRANSFAIR study. *Eur J Clin Nutr* **53**, 143–157.
59. Berner LA (1993) Roundtable discussion on milkfat, dairy foods, and coronary heart disease risk. *J Nutr* **123**, 1175–1184.
60. Aro A, Antoine JM, Pizzoferrato L, *et al.* (1998) Trans fatty acids in dairy and meat products from 14 European countries: the TRANSFAIR study. *J Food Compos Anal* **11**, 150–160.
61. Hu FB, Stampfer MJ, Manson JE, *et al.* (1999) Dietary saturated fats and their food sources in relation to the risk of



- coronary heart disease in women. *Am J Clin Nutr* **70**, 1001–1008.
62. Givens DI (2008) Session 4: challenges facing the food industry in innovating for health impact on CVD risk of modifying milk fat to decrease intake of SFA and increase intake of *cis*-MUFA. *Proc Nutr Soc* **67**, 419–427.
  63. Givens DI (2010) Milk and meat in our diet: good or bad for health? *Animal* **4**, 1941–1952.
  64. Mensink RP, Zock PL, Kester ADM, *et al.* (2003) Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr* **77**, 1146–1155.
  65. Hu FB, Stampfer MJ, Manson JE, *et al.* (1997) Dietary fat intake and the risk of coronary heart disease in women. *N Engl J Med* **337**, 1491–1499.
  66. Willett WC, Stampfer MJ, Manson JE, *et al.* (1993) Intake of *trans* fatty acids and risk of coronary heart disease among women. *Lancet* **341**, 581–585.
  67. Chardigny JM, Destailats F, Malpuech-Brugère C, *et al.* (2008) Do *trans* fatty acids from industrially produced sources and from natural sources have the same effect on cardiovascular disease risk factors in healthy subjects? Results of the *trans* Fatty Acids Collaboration (TRANSFACT) study. *Am J Clin Nutr* **87**, 558–566.
  68. Grundy SM, Brewer HB Jr, Cleeman JI, *et al.* (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. *Circulation* **109**, 433–438.
  69. Pereira MA, Jacobs DR Jr, Van Horn L, *et al.* (2002) Dairy consumption, obesity, and the insulin resistance syndrome in young adults: The CARDIA Study. *J Am Med Assoc* **287**, 2081–2089.
  70. McKeown NM, Meigs JB, Liu S, *et al.* (2004) Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham offspring cohort. *Diabetes Care* **27**, 538–546.
  71. Nelson GJ, Schmidt PC & Kelley DS (1995) Low-fat diets do not lower plasma cholesterol levels in healthy men compared to high-fat diets with similar fatty acid composition at constant caloric intake. *Lipids* **30**, 969–976.
  72. Pfeuffer M & Schrezenmeir J (2007) Milk and the metabolic syndrome. *Obes Rev* **8**, 109–118.
  73. Van Meijl LEC, Vrolix R & Mensink RP (2008) Dairy product consumption and the metabolic syndrome. *Nutr Res Rev* **21**, 148–157.
  74. Nilsson M, Stenberg M, Frid AH, *et al.* (2004) Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. *Am J Clin Nutr* **80**, 1246–1253.
  75. Nakamura Y, Yamamoto N, Sakai K, *et al.* (1995) Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. *J Dairy Sci* **78**, 1253–1257.
  76. McCarron DA & Reusser ME (2002) Hypertensive cardiovascular disease: risk reduction by dietary calcium and dairy foods. *Sci Aliments* **22**, 415–421.
  77. Nagaoka S, Futamura Y, Miwa K, *et al.* (2001) Identification of novel hypocholesterolemic peptides derived from bovine milk $\beta$ -lactoglobulin. *Biochem Biophys Res Commun* **281**, 11–17.
  78. Denke MA, Fox MM & Schulte MC (1993) Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men. *J Nutr* **123**, 1047–1053.
  79. Yaffe K (2007) Metabolic syndrome and cognitive decline. *Curr Alzheimer Res* **4**, 123–126.
  80. Yaffe K, Kanaya A, Lindquist K, *et al.* (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. *J Am Med Assoc* **292**, 2237–2242.
  81. Launer LJ, Masaki K, Petrovitch H, *et al.* (1981) The association between midlife blood pressure levels and late-life cognitive function: The Honolulu-Asia Aging Study. *J Am Med Assoc* **274**, 1846–1851.
  82. Qiu C, Winblad B & Fratiglioni L (2005) The age-dependent relation of blood pressure to cognitive function and dementia. *Lancet Neurol* **4**, 487–499.
  83. Gregg EW, Yaffe K, Cauley JA, *et al.* (2000) Is diabetes associated with cognitive impairment and cognitive decline among older women? *Arch Intern Med* **160**, 174–180.
  84. Yaffe K, Blackwell T, Kanaya AM, *et al.* (2004) Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. *Neurology* **63**, 658–663.
  85. Moroney JT, Tang MX, Berglund L, *et al.* (1999) Low-density lipoprotein cholesterol and the risk of dementia with stroke. *J Am Med Assoc* **282**, 254–260.
  86. Yaffe K, Barrett-Connor E, Lin F, *et al.* (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. *Arch Neurol* **59**, 378–384.
  87. Whitmer RA, Sidney S, Selby J, *et al.* (2005) Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology* **64**, 277–281.
  88. Launer LJ (2002) Demonstrating the case that AD is a vascular disease: epidemiologic evidence. *Ageing Res Rev* **1**, 61–77.
  89. Yaffe K, Lindquist K, Penninx EM, *et al.* (2003) Inflammatory markers and cognition in well-functioning African-American and white elders. *Neurology* **61**, 76–80.
  90. Fewlass DC, Noboa K, Pi-Sunyer FX, *et al.* (1978) Obesity-related leptin regulates Alzheimer's A $\beta$ . *FASEB J* **18**, 1870–1878.
  91. Benoit SC, Clegg DJ, Seeley RJ, *et al.* (2004) Insulin and leptin as adiposity signals. *Recent Prog Horm Res* **59**, 267–285.
  92. Luchsinger JA, Tang MX, Shea S, *et al.* (2004) Hyperinsulinemia and risk of Alzheimer disease. *Neurology* **63**, 1187–1192.
  93. Luchsinger JA, Tang MX, Stern Y, *et al.* (2001) Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. *Am J Epidemiol* **154**, 635–641.
  94. Yaffe K, Blackwell T, Whitmer RA, *et al.* (2006) Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. *J Nutr Health Aging* **10**, 292–295.
  95. American Diabetes Association (2001) Postprandial blood glucose (consensus statement). *Diabetes Care* **24**, 775–778.
  96. Polonsky KS, Given BD, Hirsch LJ, *et al.* (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. *N Engl J Med* **318**, 1231–1239.
  97. Pfeifer MA, Halter JB & Porte D Jr (1981) Insulin secretion in diabetes mellitus. *Am J Med* **70**, 579–588.
  98. Del Prato S, Leonetti F, Simonson DC, *et al.* (1994) Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. *Diabetologia* **37**, 1025–1035.
  99. Craft S, Murphy C & Wemstrom J (1994) Glucose effects on complex memory and nonmemory tasks: the influence of age, sex, and glucoregulatory response. *Psychobiology (Austin, TX)* **22**, 95–105.

100. Owens D & Benton D (1994) The impact of raising blood glucose on reaction times. *Neuropsychobiology* **30**, 106–113.
101. Donohoe R & Benton D (1999) Cognitive functioning is susceptible to the level of blood glucose. *Psychopharmacology* **145**, 378–385.
102. Benton D, Owens D & Parker P (1994) Blood glucose influences memory and attention in young adults. *Neuropsychologia* **32**, 595.
103. Parker P & Benton D (1995) Blood glucose levels selectively influence memory for word lists dichotically presented to the right ear. *Neuropsychologia* **33**, 843–854.
104. Clandinin M, Cheema S, Field C, *et al.* (1993) Dietary lipids influence insulin action. *Ann N Y Acad Sci* **683**, 151–163, (1 Dietary lipids and insulin action: Proceedings of the Second International Smolenice Insulin Symposium).
105. Pan J & Berdanier C (1991) Dietary fat saturation affects glucose metabolism without affecting insulin receptor number and affinity in adipocytes from BHE rats. *J Nutr* **121**, 1811.
106. Storlien L, Higgins J, Thomas T, *et al.* (2007) Diet composition and insulin action in animal models. *Br J Nutr* **83**, Suppl. 1, S85–S90.
107. Greenwood C & Winocur G (1996) Cognitive impairment in rats fed high-fat diets: a specific effect of saturated fatty-acid intake. *Behav Neurosci* **110**, 451–458.
108. Greenwood C & Winocur G (1990) Learning and memory impairment in rats fed a high saturated fat diet. *Behav Neural Biol* **53**, 74–87.
109. Greenwood C & Winocur G (2001) Glucose treatment reduces memory deficits in young adult rats fed high-fat diets. *Neurobiol Learn Mem* **75**, 179–189.
110. Messier C, Tsiakas M, Gagnon M, *et al.* (2003) Effect of age and glucoregulation on cognitive performance. *Neurobiol Aging* **24**, 985–1003.
111. Awad N, Gagnon M, Desrochers A, *et al.* (2002) Impact of peripheral glucoregulation on memory. *Behav Neurosci* **116**, 691–702.
112. Messier C, Desrochers A & Gagnon M (1999) Effect of glucose, glucose regulation, and word imagery value on human memory. *Behav Neurosci* **113**, 431–438.
113. Donohoe R & Benton D (2000) Glucose tolerance predicts performance on tests of memory and cognition. *Physiol Behav* **71**, 395–401.
114. Craft S, Asthana S, Schellenberg G, *et al.* (2000) Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. *Ann N Y Acad Sci* **903**, 222–228.
115. Kaplan R, Greenwood C, Winocur G, *et al.* (2000) Cognitive performance is associated with glucose regulation in healthy elderly persons and can be enhanced with glucose and dietary carbohydrates. *Am J Clin Nutr* **72**, 825–836.
116. Manning C, Hall J & Gold P (1990) Glucose effects on memory and other neuropsychological tests in elderly humans. *Psychol Sci* **1**, 307–311.
117. Messier C, Gagnon M & Knott V (1997) Effect of glucose and peripheral glucose regulation on memory in the elderly. *Neurobiol Aging* **18**, 297–304.
118. Parsons M & Gold P (1992) Glucose enhancement of memory in elderly humans: an inverted-U dose–response curve. *Neurobiol Aging* **13**, 401–404.
119. Vanhanen M, Koivisto K, Kuusisto J, *et al.* (1998) Cognitive function in an elderly population with persistent impaired glucose tolerance. *Diabetes Care* **21**, 398–402.
120. Lamport DJ, Lawton CL, Mansfield MW, *et al.* (2009) Impairments in glucose tolerance can have a negative impact on cognitive function: a systematic research review. *Neurosci Biobehav Rev* **33**, 394–413.
121. Leibson CL, Rocca WA, Hanson VA, *et al.* (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. *Am J Epidemiol* **145**, 301–308.
122. Ott A, Stolk RP, Hofman A, *et al.* (1996) Association of diabetes mellitus and dementia: The Rotterdam Study. *Diabetologia* **39**, 1392–1397.
123. Ott A, Stolk RP, Van Harskamp F, *et al.* (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. *Neurology* **53**, 1937–1942.
124. Korhonen H & Pihlanto A (2007) Technological options for the production of health-promoting proteins and peptides derived from milk and colostrum. *Curr Pharm Des* **13**, 829–843.
125. Skov A, Toubro S, Rønn B, *et al.* (1999) Randomized trial on protein vs carbohydrate in *ad libitum* fat reduced diet for the treatment of obesity. *Int J Obes* **23**, 528–536.
126. Crovetti R, Porrini M, Santangelo A, *et al.* (1998) The influence of thermic effect of food on satiety. *Eur J Clin Nutr* **52**, 482–488.
127. Westerterp-Plantenga MS, Nieuwenhuizen A, Tomé D, *et al.* (2009) Dietary protein, weight loss, and weight maintenance. *Annu Rev Nutr* **29**, 21–41.
128. Zemel MB (2009) Proposed role of calcium and dairy food components in weight management and metabolic health. *Phys Sportsmed* **37**, 29–39.
129. Belobrajdic D, McIntosh G & Owens J (2003) Whey proteins protect more than red meat against azoxymethane induced ACF in Wistar rats. *Cancer Lett* **198**, 43–51.
130. Badger T, Ronis M & Hakkak R (2001) Developmental effects and health aspects of soy protein isolate, casein, and whey in male and female rats. *Int J Toxicol* **20**, 165–174.
131. Hays NP, Kim H, Wells AM, *et al.* (2009) Effects of whey and fortified collagen hydrolysate protein supplements on nitrogen balance and body composition in older women. *J Am Diet Assoc* **109**, 1082–1087.
132. O'Rourke RW (2009) Molecular mechanisms of obesity and diabetes: at the intersection of weight regulation, inflammation, and glucose homeostasis. *World J Surg* **33**, 2007–2013.
133. Belobrajdic D, McIntosh G & Owens J (2004) A high-whey-protein diet reduces body weight gain and alters insulin sensitivity relative to red meat in Wistar rats. *J Nutr* **134**, 1454–1458.
134. Craft S, Newcomer J, Kanne S, *et al.* (1996) Memory improvement following induced hyperinsulinemia in Alzheimer's disease. *Neurobiol Aging* **17**, 123–130.
135. Gasparini L, Gouras GK, Wang R, *et al.* (2001) Stimulation of  $\beta$ -amyloid precursor protein trafficking by insulin reduces intraneuronal  $\beta$ -amyloid and requires mitogen-activated protein kinase signaling. *J Neurosci* **21**, 2561–2570.
136. Kurochkin IV & Goto S (1994) Alzheimer's  $\beta$ -amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. *FEBS Lett* **345**, 33–37.
137. Qiu WQ, Walsh DM, Ye Z, *et al.* (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid  $\beta$ -protein by degradation. *J Biol Chem* **273**, 32730–32738.
138. Schwartz MW, Figlewicz DF, Kahn SE, *et al.* (1990) Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. *Peptides* **11**, 467–472.
139. Gerozissis K, Orosco M, Rouch C, *et al.* (1993) Basal and hyperinsulinemia-induced immunoreactive hypothalamic insulin changes in lean and genetically obese Zucker rats revealed by microdialysis. *Brain Res* **611**, 258–263.

140. Hoyer S (2002) The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. *J Neural Transm* **109**, 991–1002.
141. Hong M & Lee VMY (1954) Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. *J Biol Chem* **272**, 19547–19553.
142. Sabayan B, Foroughinia F, Mowla A, *et al.* (2008) Role of insulin metabolism disturbances in the development of Alzheimer disease: mini review. *Am J Alzheimer's Dis Other Demen* **23**, 192–199.
143. Fishel MA, Watson GS, Montine TJ, *et al.* (2005) Hyperinsulinemia provokes synchronous increases in central inflammation and  $\beta$ -amyloid in normal adults. *Arch Neurol* **62**, 1539–1544.
144. Facchini FS, Hua NW, Reaven GM, *et al.* (2000) Hyperinsulinemia: the missing link among oxidative stress and age-related diseases? *Free Radic Biol Med* **29**, 1302–1306.
145. Östman EM, Liljeberg Elmståhl HGM & Björck IME (2001) Inconsistency between glycemic and insulinemic responses to regular and fermented milk products. *Am J Clin Nutr* **74**, 96–100.
146. Frid AH, Nilsson M, Holst JJ, *et al.* (2005) Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. *Am J Clin Nutr* **82**, 69–75.
147. Boirie Y, Dangin M, Gachon P, *et al.* (1997) Slow and fast dietary proteins differently modulate postprandial protein accretion. *Proc Natl Acad Sci U S A* **94**, 14930–14935.
148. Floyd JC Jr, Fajans SS, Conn JW, *et al.* (1966) Stimulation of insulin secretion by amino acids. *J Clin Invest* **45**, 1487–1502.
149. Nilsson M, Holst JJ & Björck IME (2007) Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. *Am J Clin Nutr* **85**, 996–1004.
150. Fonseca V (2003) Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. *Curr Med Res Opin* **19**, 635–641.
151. Goff D (2009) Dairy chemistry and physics. *Dairy Sci Technol*. <http://www.foodsci.uoguelph.ca/dairyedu/chem.html> (cited 8 September 2009).
152. Kitts DD & Weiler K (2003) Bioactive proteins and peptides from food sources. Applications of bioprocess used in isolation and recovery. *Curr Pharm Des* **9**, 1309–1323.
153. Nakamura H, Iwamoto M, Ogata T, *et al.* (2008) Effects of milk casein-derived peptides on absolute oxyhaemoglobin concentrations in the prefrontal area and on work efficiency after mental stress loading in male students. *J Int Med Res* **36**, 638–647.
154. Korhonen H & Pihlanto A (2006) Bioactive peptides: production and functionality. *Int Dairy J* **16**, 945–960.
155. Korhonen H (2009) Milk-derived bioactive peptides: from science to applications. *J Funct Foods* **1**, 177–187.
156. Donkor ON, Henriksson A, Vasiljevic T, *et al.* (2007) Proteolytic activity of dairy lactic acid bacteria and probiotics as determinant of growth and *in vitro* angiotensin-converting enzyme inhibitory activity in fermented milk. *Lait* **87**, 21–38.
157. Murray BA & FitzGerald RJ (2007) Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. *Curr Pharm Des* **13**, 773–791.
158. Clare DA & Swaisgood HE (2000) Bioactive milk peptides: a prospectus. *J Dairy Sci* **83**, 1187–1195.
159. Meisel H, Goepfert A & Günther S (1997) ACE-inhibitory activities in milk products. *Milchwissenschaft* **52**, 307–311.
160. Smacchi E & Gobetti M (1998) Peptides from several Italian cheeses inhibitory to proteolytic enzymes of lactic acid bacteria, *Pseudomonas fluorescens* ATCC 948 and to the angiotensin I-converting enzyme. *Enzyme Microb Technol* **22**, 687–694.
161. Saito T, Nakamura T, Kitazawa H, *et al.* (2000) Isolation and structural analysis of antihypertensive peptides that exist naturally in Gouda cheese. *J Dairy Sci* **83**, 1434–1440.
162. Teschemacher H, Koch G & Brantl V (1997) Milk protein-derived opioid receptor ligands. *Biopolymers* **43**, 99–117.
163. Daniel H, Vohwinkel M & Rehner G (1990) Effect of casein and  $\beta$ -casomorphins on gastrointestinal motility in rats. *J Nutr* **120**, 252–257.
164. Sturmer RA & Chang KJ (1988) Opioid peptide content in infant formulas. *Pediatr Res* **23**, 4–10.
165. Haque E, Chand R & Kapila S (2009) Biofunctional properties of bioactive peptides of milk origin. *Food Rev Int* **25**, 28–43.
166. Tidona F, Criscione A, Guastella AM, *et al.* (2009) Peptidi bioattivi nei prodotti lattiero-caseari (Bioactive peptides in dairy products). *Ital J Anim Sci* **8**, 315–340.
167. Pihlanto A (2006) Antioxidative peptides derived from milk proteins. *Int Dairy J* **16**, 1306–1314.
168. Zommarà MA, Toubou H & Imaizumi K (2002) Supplementing bovine milk immunoglobulin G prevents rats fed on a vitamin E-deficient diet from developing peroxidation stress. *Ann Nutr Metab* **46**, 97–102.
169. Kullisaar T, Songisepp E, Mikelsaar M, *et al.* (2003) Antioxidative probiotic fermented goats' milk decreases oxidative stress-mediated atherogenicity in human subjects. *Br J Nutr* **90**, 449–456.
170. Zemel MB, Sun X, Sobhani T, *et al.* (2010) Effects of dairy compared with soy on oxidative and inflammatory stress in overweight and obese subjects. *Am J Clin Nutr* **91**, 16–22.
171. Sekiya S, Kobayashi Y, Kita E, *et al.* (1992) Antihypertensive effects of tryptic hydrolysate of casein on normotensive and hypertensive volunteers. *J Jpn Soc Nutr Food Sci* **45**, 513–517.
172. Hata Y, Yamamoto M, Ohni M, *et al.* (1996) A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. *Am J Clin Nutr* **64**, 767–771.
173. Seppo L, Jauhainen T, Poussa T, *et al.* (2003) A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. *Am J Clin Nutr* **77**, 326–330.
174. Seppo L, Kerojoki O, Suomalainen T, *et al.* (2002) The effect of a *Lactobacillus helveticus* LBK-16 H fermented milk on hypertension – a pilot study on humans. *Milchwissenschaft* **57**, 124–127.
175. Mizushima S, Ohshige K, Watanabe J, *et al.* (2004) Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. *Am J Hypertens* **17**, 701–706.
176. Hatakeyama E, Yamaguchi M, Muramoto K, *et al.* (2003) Modulating effects of soy protein isolate and soy protein hydrolysate on human brain function. *Soy Protein Res Jpn* **6**, 147–152.
177. Williamson MP (1994) The structure and function of proline-rich regions in proteins. *Biochem J* **297**, 249–260.
178. Boldogh I & Kruzel ML (2008) Colostrinin(TM): an oxidative stress modulator for prevention and treatment of age-related disorders. *J Alzheimer's Dis* **13**, 303–321.
179. Kruzel ML, Polanowski A, Wilusz T, *et al.* (2004) The alcohol-induced conformational changes in casein micelles:



- a new challenge for the purification of Colostrin. *Protein J* **23**, 127–133.
180. Janusz M, Inglot AD, Lisowski J, *et al.* (1996) Colostrin identified as new cytokine. *Eur Cytokine Netw* **7**, 512.
  181. Gladkevich A, Bosker F, Korf J, *et al.* (2007) Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders – therapeutic potential or a mirage? *Prog Neuropsychopharmacology Biol Psychiatry* **31**, 1347–1355.
  182. Janusz M, Staroscik K, Zimecki M, *et al.* (1981) Chemical and physical characterization of a proline-rich polypeptide from sheep colostrum. *Biochem J* **199**, 9–15.
  183. Zabłocka A, Janusz M, Macała J, *et al.* (2005) A proline-rich polypeptide complex and its nonapeptide fragment inhibit nitric oxide production induced in mice. *Regul Peptides* **125**, 35–39.
  184. Popik P, Bobula B, Janusz M, *et al.* (1999) Colostrin, a polypeptide isolated from early milk, facilitates learning and memory in rats. *Pharmacol Biochem Behav* **64**, 183–189.
  185. Leszek J, Inglot AD, Janusz M, *et al.* (1999) Colostrin®: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study. *Arch Immunol Ther Exp* **47**, 377–385.
  186. Bilikiewicz A & Gaus W (2004) Colostrin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. *J Alzheimer's Dis* **6**, 17–26.
  187. Swaisgood H (1995) Nitrogenous components of milk. In *Handbook of Milk Composition*, p. 465 [RG Jensen, editor]. San Diego, CA: Academic Press.
  188. Montagne P, Cuilliere ML, Mole C, *et al.* (1999) Immunological and nutritional composition of human milk in relation to prematurity and mothers' parity during the first 2 weeks of lactation. *J Pediatr Gastroenterol Nutr* **29**, 75–80.
  189. Chatterton DEW, Smithers G, Roupas P, *et al.* (2006) Bioactivity of beta-lactoglobulin and alpha-lactalbumin – technological implications for processing. *Int Dairy J* **16**, 1229–1240.
  190. Heine W, Radke M, Wutzke K, *et al.* (1996) Lactalbumin-enriched low-protein infant formulas: a comparison to breast milk feeding. *Acta Paediatrica* **85**, 1024–1028.
  191. Lehnert H & Wurtman RJ (1993) Amino acid control of neurotransmitter synthesis and release: physiological and clinical implications. *Psychother Psychosom* **60**, 18–32.
  192. Markus C, Olivier B, Panhuysen G, *et al.* (2000) The bovine protein alpha-lactalbumin increases the plasma ratio of tryptophan to the other large neutral amino acids, and in vulnerable subjects raises brain serotonin activity, reduces cortisol concentration, and improves mood under stress. *Am J Clin Nutr* **71**, 1536–1544.
  193. Markus C, Jonkman L, Lammers J, *et al.* (2005) Evening intake of alpha-lactalbumin increases plasma tryptophan availability and improves morning alertness and brain measures of attention. *Am J Clin Nutr* **81**, 1026–1033.
  194. Orosco M, Rouch C, Beslot F, *et al.* (2004) Alpha-lactalbumin-enriched diets enhance serotonin release and induce anxiolytic and rewarding effects in the rat. *Behav Brain Res* **148**, 1–10.
  195. Jacobs BL, Van Praag H & Gage FH (2000) Adult brain neurogenesis and psychiatry: a novel theory of depression. *Mol Psychiatry* **5**, 262–269.
  196. Jouvet M (1999) Sleep and serotonin: an unfinished story. *Neuropsychopharmacology (New York, NY)* **21**, 24–27.
  197. Minet-Ringuet J, Le Ruyet P, Tome D, *et al.* (2004) A tryptophan-rich protein diet efficiently restores sleep after food deprivation in the rat. *Behav Brain Res* **152**, 335–340.
  198. Markus C, Olivier B, Panhuysen G, *et al.* (2000) The bovine protein alpha-lactalbumin increases the plasma Trp/LNAA ratio, and in vulnerable subjects raises brain serotonin activity and decreases cortisol and mood under stress. *Am J Clin Nutr* **71**, 1536–1544.
  199. Markus CR, Olivier B & De Haan EHF (2002) Whey protein rich in alpha-lactalbumin increases the ratio of plasma tryptophan to the sum of the other large neutral amino acids and improves cognitive performance in stress-vulnerable subjects. *Am J Clin Nutr* **75**, 1051–1056.
  200. Schmitt J, Jorissen B, Dye L, *et al.* (2005) Memory function in women with premenstrual complaints and the effect of serotonergic stimulation by acute administration of an alpha-lactalbumin protein. *J Psychopharmacol* **19**, 375–384.
  201. Vaswani M, Linda F & Ramesh S (2003) Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. *Prog Neuropsychopharmacol Biol Psychiatry* **27**, 85–102.
  202. Booij L, Van der Does A & Riedel W (2003) Monoamine depletion in psychiatric and healthy populations: review. *Mol Psychiatry* **8**, 951–973.
  203. Merens W, Booij L, Markus R, *et al.* (2007) The effects of a diet enriched with alpha-lactalbumin on mood and cortisol response in unmedicated recovered depressed subjects and controls. *Br J Nutr* **94**, 415–422.
  204. Booij L, Merens W, Markus C, *et al.* (2006) Diet rich in alpha-lactalbumin improves memory in unmedicated recovered depressed patients and matched controls. *J Psychopharmacol* **20**, 526–535.
  205. Verschoor E, Finlayson G, Blundell J, *et al.* (2010) Effects of an acute alpha-lactalbumin manipulation on mood and food hedonics in high- and low-trait anxiety individuals. *Br J Nutr* **104**, 595–602.
  206. US Department of Agriculture (2003) USDA Nutrient Database for Standard Reference, Release 16. Nutrient Data Laboratory Home Page.
  207. Clarke R (2008) B-vitamins and prevention of dementia. *Proc Nutr Soc* **67**, 75–81.
  208. Vogel T, Dali-Youcef N, Kaltenbach G, *et al.* (2009) Homocysteine, vitamin B<sub>12</sub>, folate and cognitive functions: a systematic and critical review of the literature. *Int J Clin Practice* **63**, 1061–1067.
  209. Wang HX, Wahlin Å, Basun H, *et al.* (2001) Vitamin B<sub>12</sub> and folate in relation to the development of Alzheimer's disease. *Neurology* **56**, 1188–1194.
  210. Nilsson K, Gustafson L, Faldt R, *et al.* (1996) Hyperhomocysteinaemia – a common finding in a psychogeriatric population. *Eur J Clin Invest* **26**, 853–859.
  211. Nilsson K, Gustafson L & Hultberg B (2001) Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. *Int J Geriatr Psychiatry* **16**, 609–614.
  212. Miller AL (2003) The methionine–homocysteine cycle and its effects on cognitive diseases. *Altern Med Rev* **8**, 7–19.
  213. West RL, Lee JM & Maroun LE (1995) Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. *J Mol Neurosci* **6**, 141–146.
  214. Rogaeve EI, Lukiw WJ, Lavrushina O, *et al.* (1994) The upstream promoter of the A $\beta$ -amyloid precursor protein gene (APP) shows differential patterns of methylation in human brain. *Genomics* **22**, 340–347.

215. Kruman II, Culmsee C, Chan SL, *et al.* (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. *J Neurosci* **20**, 6920–6926.
216. Ho PI, Collins SC, Dhitavat S, *et al.* (2001) Homocysteine potentiates  $\text{I}^2$ -amyloid neurotoxicity: role of oxidative stress. *J Neurochem* **78**, 249–253.
217. Elias MF, Sullivan LM, D'Agostino RB, *et al.* (2005) Homocysteine and cognitive performance in the Framingham Offspring Study: age is important. *Am J Epidemiol* **162**, 644–653.
218. Clarke R, Smith AD, Jobst KA, *et al.* (1998) Folate, vitamin B<sub>12</sub>, and serum total homocysteine levels in confirmed Alzheimer disease. *Arch Neurol* **55**, 1449–1455.
219. Joosten E, Lesaffre E, Riezler R, *et al.* (1997) Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? *J Gerontol A Biol Sci Med Sci* **52**, M76–M79.
220. US Department of Health and Human Services & US Department of Agriculture (2005) *Dietary Guidelines for Americans*, 6th ed. Washington, DC: US Government. <http://www.health.gov/dietaryguidelines>.
221. Gao X, Wilde PE, Lichtenstein AH, *et al.* (2006) Meeting adequate intake for dietary calcium without dairy foods in adolescents aged 9 to 18 years (National Health and Nutrition Examination Survey 2001–2002). *J Am Diet Assoc* **106**, 1759–1765.
222. Astrup A, Chaput JP, Gilbert JA, *et al.* (2010) Dairy beverages and energy balance. *Physiol Behav* **100**, 67–75.
223. Major GC, Chaput JP, Ledoux M, *et al.* (2008) Recent developments in calcium-related obesity research. *Obes Rev* **9**, 428–445.
224. Govers MJAP, Termont DSML, Van Aken GA, *et al.* (1994) Characterization of the adsorption of conjugated and unconjugated bile acids to insoluble, amorphous calcium phosphate. *J Lipid Res* **35**, 741–748.
225. Gacs G & Bartrop D (1977) Significance of Ca soap formation for calcium absorption in the rat. *Gut* **18**, 64–68.
226. Ditscheid B, Keller S & Jahreis G (2005) Cholesterol metabolism is affected by calcium phosphate supplementation in humans. *J Nutr* **135**, 1678–1682.
227. Payne ME, Anderson JJB & Steffens DC (2008) Calcium and vitamin D intakes may be positively associated with brain lesions in depressed and nondepressed elders. *Nutr Res* **28**, 285–292.
228. Bolland MJ, Barber PA, Doughty RN, *et al.* (2008) Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. *BMJ* **336**, 262–266.
229. Daly R, Ebeling P, Khan B, *et al.* (2009) Effect of calcium–vitamin D<sub>3</sub> fortified milk on abdominal aortic calcification in older men: retrospective analysis of a 2-year randomized controlled trial. *J Bone Miner Res* **24**, 1215.
230. Thibault O, Gant JC & Landfield W (2007) Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. *Aging Cell* **6**, 307–317.
231. Levy J, Gavin JR 3rd & Sowers JR (1994) Diabetes mellitus: a disease of abnormal cellular calcium metabolism? *Am J Med* **96**, 260–273.
232. Stutzmann GE, Smith I, Caccamo A, *et al.* (2006) Enhanced ryanodine receptor recruitment contributes to Ca<sup>2+</sup> disruptions in young, adult, and aged Alzheimer's disease mice. *J Neurosci* **26**, 5180–5189.
233. Potier B, Rascol O, Jazat F, *et al.* (1992) Alterations in the properties of hippocampal pyramidal neurons in the aged rat. *Neuroscience* **48**, 793–806.
234. Landfield PW & Pitler TA (1984) Prolonged Ca<sup>2+</sup>-dependent afterhyperpolarizations in hippocampal neurons of aged rats. *Science* **226**, 1089–1092.
235. Kerr DS, Campbell LW, Hao SY, *et al.* (1989) Corticosteroid modulation of hippocampal potentials: increased effect with aging. *Science* **245**, 1505–1509.
236. Moyer JR Jr, Thompson LT, Black JP, *et al.* (1992) Nimodipine increases excitability of rabbit CA1 pyramidal neurons in an age- and concentration-dependent manner. *J Neurophysiol* **68**, 2100–2109.
237. Disterhoft JF, Thompson LT, Moyer JR Jr, *et al.* (1996) Calcium-dependent afterhyperpolarization and learning in young and aging hippocampus. *Life Sci* **59**, 413–420.
238. Hemond P & Jaffe DB (2005) Caloric restriction prevents aging-associated changes in spike-mediated Ca<sup>2+</sup> accumulation and the slow afterhyperpolarization in hippocampal CA1 pyramidal neurons. *Neuroscience* **135**, 413–420.
239. Thibault O, Hadley R & Landfield PW (2001) Elevated post-synaptic [Ca<sup>2+</sup>]<sub>i</sub> and L-type calcium channel activity in aged hippocampal neurons: relationship to impaired synaptic plasticity. *J Neurosci* **21**, 9744–9756.
240. Campbell LW, Hao SY, Thibault O, *et al.* (1996) Aging changes in voltage-gated calcium currents in hippocampal CA1 neurons. *J Neurosci* **16**, 6286–6295.
241. Thibault O & Landfield PW (1996) Increase in single L-type calcium channels in hippocampal neurons during aging. *Science* **272**, 1017–1020.
242. Smith IF, Hitt B, Green KN, *et al.* (2005) Enhanced caffeine-induced Ca<sup>2+</sup> release in the 3xTg-AD mouse model of Alzheimer's disease. *J Neurochem* **94**, 1711–1718.
243. Kopp-Hoolihan L (2001) Prophylactic and therapeutic uses of probiotics: a review. *J Am Diet Assoc* **101**, 229–241.
244. Butt H, Dunstan R & McGregor N, *et al.* (2001) Bacterial colonisation in patients with persistent fatigue. In *Proceedings of the AHMF International Clinical and Scientific Conference*, Sydney, Australia.
245. Logan A & Katzman M (2005) Major depressive disorder: probiotics may be an adjuvant therapy. *Med Hypotheses* **64**, 533–538.
246. Desbonnet L, Garrett L, Clarke G, *et al.* (2008) The probiotic *Bifidobacteria infantis*: an assessment of potential antidepressant properties in the rat. *J Psychiatr Res* **43**, 164–174.
247. Benton D, Williams C & Brown A (2007) Impact of consuming a milk drink containing a probiotic on mood and cognition. *Eur J Clin Nutr* **61**, 355–361.
248. Lomer MCE, Parkes GC & Sanderson JD (2008) Review Article: lactose intolerance in clinical practice – myths and realities. *Aliment Pharmacol Ther* **27**, 93–103.